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1 Introduction 
 
1.1 The Immune System – Innate and Adaptive Immunity 
 
In order to protect from pathogenic infections all higher eukaryotic species developed a 
complex system of defence mechanisms entirely designated as immune system. The defence 
against various pathogens like bacteria, fungi, viruses and parasites as well as the recognition 
and elimination of virally transformed or tumour cells is exerted by distinct specialised im-
mune cells originating from the bone marrow and circulating in the blood. The immune sys-
tem can be divided into two arms; the innate and the adaptive system. Both systems interact 
and complement each other to provide the best possible protection of the body against various 
pathogens and infectious agents.  
 
1.1.1 The innate immune system 
In case of an infection by a pathogen, the different components of the innate immune sys-
tem become activated immediately, representing therefore the first line of defence. The innate 
immune system offers a first barrier against pathogen penetration as well as a general defence 
that is only to certain extend antigen-specific. Physical barriers (skin and mucosal mem-
branes), which prevent the infection by a pathogen, are combined with a set of cellular 
mechanisms and soluble factors that are intended to eliminate a pathogen once the infection 
occurred. The most important cells responding to an infection are phagocytic white blood 
cells like macrophages and neutrophils, able to ingest and kill microbes by producing toxic 
chemicals and degradative enzymes, and Natural Killer (NK) cells, which mediate lysis of 
target cells. During the early phase of the innate immune response, both cell types produce 
cytokines, which cause local inflammation and activate the adaptive immune system. NK 
cells, which are crucial for early defence against infections and tumour surveillance, represent 
a connecting cell type between innate and adaptive immune system and will be described in 
more detail in the next paragraphs. 
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In order to be alerted, the innate immune system displays a set of receptors, which senses 
the presence of a pathogen or of danger. These activating receptors are germline-encoded and 
thus can only detect general patterns, so called pathogen-associated molecular patterns 
(PAMP). PAMPs are molecules selectively expressed by the pathogen, such as lipopolysac-
caride (LPS), flagellin or peptidoglycan. They are recognized by specialized receptors like 
Toll-like receptors (TLR) expressed on dendritic cells (DCs) and macrophages, and activating 
receptors expressed on NK cells (1). The binding of PAMP to cells of the innate immune sys-
tem results in killing of the pathogens and secretion of pro-inflammatory cytokines. The in-
nate immune system acts within minutes to hours after an infection and many of the effector 
and costimulatory molecules generated during this early phase of the immune response play 
an important role for the slower developing adaptive response. 
 
1.1.2 The adaptive immune system 
Although 90% of infections are eliminated by mechanisms of the innate immune system, 
some pathogens escape these defences and the adaptive immune system needs to be activated. 
Soluble factors belonging to the complement system and chemokines and cytokines secreted 
by innate immune cells induce the recruitment of lymphocytes and the activation of the adap-
tive immune system. Adaptive immunity is mainly exerted by two types of lymphocytes, 
namely T cells and B cells. Different from innate immune cells, T and B cells express antigen 
specific receptors (T cell receptor, TCR and B cell receptor, BCR) which undergo genetic re-
combination in somatic cells. This process provides with a highly diverse repertoire of recep-
tors able to recognize plenty different pathogen-derived antigens. In contrast to innate immu-
nity, adaptive immunity not only contributes to pathogen clearance but also is essential for the 
formation of an immunological memory – a feature leading to fast acting responses in case of 
reinfection. The protection of the extracellular fluids and spaces is mediated by the humoral 
immune response, in which antibodies produced by B cells bind to extracellular pathogens 
and toxins. Activation of naïve B cells is triggered by binding of the BCR to its specific anti-
gen and it usually requires the help of T cells. Following antigen binding to the BCR, B cells 
become activated and differentiate into antibody secreting plasma cells. The secreted antibod-
ies bind specifically to the antigen on the pathogen surface, subsequently leading to comple-
ment activation and phagocytosis of the pathogen. Also NK cells recognize target cells coated 
with antibodies, which leads to lysis of the target cell by so-called antibody dependent cellular 
cytotoxicity (ADCC).  
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Different from B cells, T cells are not able to recognize the pathogen directly, but need the 
help of a professional antigen-presenting cell (APC) such as a DC. DCs which have been ac-
tivated by pathogen-derived PAMP degrade the pathogen in a specialized cellular compart-
ment named proteasome and present the antigens as small peptides on major histocompatibil-
ity complex (MHC) molecules expressed on their surface. The peptide-MHC complex 
presented by DCs is recognized by the specific TCR expressed on a T cell, leading to T cell 
activation and clonal expansion. Antigen presentation and activation of naive T cells occur in 
secondary lymphoid organs where DCs migrate to, after they have encountered the pathogen 
in the peripheral tissue. Among T cells, two populations can be distinguished, CD4+ T helper 
(TH) cells and CD8+ cytotoxic T cells (CTL). The latter recognize peptides derived from intra-
cellular pathogens, like viruses, protozoas and some bacteria, that are presented via ubiqui-
tously expressed MHC class I molecules. Subsequent, CD8+ T cell activation and release of 
cytotoxic molecules leads to killing of the infected target cells. Conversely, antigens derived 
from extracellular pathogens are taken up by phagocytosis and presented by DCs on MHC 
class II molecules resulting in activation of CD4+ TH cells. TH cells do not only stimulate in-
nate cells such as macrophages but also play a crucial role in activating other adaptive cells, 
like B cells and CD8+ CTLs thereby contributing to the elimination of the pathogen. 
Summing up, innate and adaptive immune responses intensively cooperate with each other 
thereby both contributing to pathogen clearance. While the innate immune system is crucial 
during the early phase of a primary infection but does not provide immunological memory, 
the adaptive immune system takes longer to be activated but endows with immunological 
memory, which allows an even quicker response in case of re-exposure to the same pathogen. 
 
1.2 General aspects of NK cell biology and activation 
 
NK cells are large granular lymphocytes able to kill malignant, infected or ‘stressed’ cells 
and to produce inflammatory cytokines. Therefore, they play an important role in the elimina-
tion of pathogens and tumours. In particular, NK cells contribute to the defence against para-
sites and intracellular bacteria, and they are critical for controlling several types of viral infec-
tions (2, 3). Under steady state conditions, NK cells are widely distributed in lymphoid and 
non-lymphoid organs, but can rapidly migrate to inflamed tissue in response to different 
chemoattractans (2).  
Introduction  4 
 
In contrast to responses of the adaptive immune system, the NK cell response is immediate, 
and plays its most important role during the first few days of infection with pathogens.  
Unlike T and B cells, the specificity of NK cells for target cells is not determined by single 
antigen receptors encoded by genes undergoing somatic recombination. Instead, NK cells use 
a range of activating and inhibitory receptors similar to other innate immune cells. The main 
effector functions of NK cells, such as cytokine production and cytotoxicity, are tightly regu-
lated by a balance between these activating and inhibitory signals. Thus, after engagement of 
multiple activating receptors expressed on their surface by ligands up-regulated on trans-
formed or infected cells, NK cells can produce cytokines and kill target cells whereas en-
gagement of inhibitory receptors by MHC class I molecules prevent normal cells from killing 
by NK cells (Figure 1).  
Expression of ligands for activating NK cell receptors by pathogen-infected cells or tumour 
cells can stimulate NK cells, which subsequently kill the target cell by the release of lytic 
granules. Those granules include perforin and granzymes, which induce the generation of 
pores in the cellular membrane and the activation of caspase cascades resulting in apoptosis of 
the target cell (Natural cytotoxicity). The cytotoxic pathway can also be initiated after en-
gagement of the constant fraction  receptor III (FcRIII, CD16) expressed on the surface of 
NK cells by antibodies bound to a cellular target (ADDC) (5), allowing NK cells to specifi-
cally kill infected cells with the help of the adaptive immune system. 
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Figure 1: The balance of activating and inhibitory signals determines NK cell - target 
cell interaction. 
NK cells are tolerant to cells expressing normal levels of self-MHC class I molecules and low levels of 
activating ligands. If this balance is distorted by down-regulation of MHC class I, killing is mediated 
due to missing self-recognition. Conversely, up-regulation of activating ligands leads to killing due to 
induced self-recognition, even when MHC class I is still present on the cell surface. Figure adapted 
from Raulet et al (4). 
 
In addition, activated NK cells represent an early source of cytokines, especially Interferon- 
(IFN-), tumour-necrosis-factor (TNF) and granulocyte-macrophage colony-stimulating factor 
(GM-CSF) which lead to the recruitment of other immune cells and to the activation of antivi-
ral responses in infected cells (6). Furthermore, they enhance production of toxic metabolites 
in macrophages and induce DC maturation and production of Interleukin (IL)-12 in DCs. 
Through production of cytokines, NK cells are also able to shape the adaptive immune re-
sponse by driving the differentiation of naive T cells into IFN- producing TH1 cells (2). 
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Although NK cells apparently display the ability to become directly activated by diseased 
cells, it has been postulated that for proper NK cell priming, APC are required. Thus, NK cells 
can be activated by DC-derived cytokines such as IL-15 and they can produce IFN- in re-
sponse to IL-12 and IL-18 in the absence of additional activating signals. In addition, IL-2, a 
cytokine mainly produced by T cells, can activate NK cells resulting in extensive proliferation 
and maturation. 
 
1.3 NK cells subsets and differentiation
 
Human NK cells are defined phenotypically by expression of CD56 and lack of CD3 and 
comprise approximately 10-15% of lymphocytes circulating in the blood (7). Based upon 
their cell-surface density of CD56, two populations of human NK cells can be distinguished. 
The majority (95%) of human peripheral blood (PB)-NK cells express low-levels of CD56 
(CD56dim), high levels of the FcRIII CD16 and lytic granules to rapidly mediate cytotoxicity 
(8, 9). The remaining PB-NK cells ( 5%) are represented by CD56bright cells (10), which con-
versely express high density of CD56 and very low levels of lytic granules, secrete larger 
amounts of cytokines and proliferate much more vigorously than CD56dim NK cells upon acti-
vation (Figure 2).  
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Figure 2: Schema of human NK cell subsets 
CD56bright cells express low levels of lytic granules and Fc receptor III (CD16), no killer cell Ig-
like receptor (KIR), but high levels of the inhibitory CD94-NKG2A C-type lectin NK receptor (NKR). 
CD56bright secrete large amounts of cytokines and proliferate much more vigorously than CD56dim NK 
cells upon activation with cytokines. In contrast, CD56dim display high levels of CD16, KIR and lytic 
granules to rapidly mediate cytotoxicity. Figure adapted from Cooper et al (10). 
 
1.3.1 NK receptors 
NK receptors specific for MHC class I molecules are crucial for distinguishing normal 
cells from transformed and/ or foreign cells and they exist in both activating and inhibitory 
forms. In most cases, ligands for activating receptors are pathogen-encoded molecules or self-
proteins whose expression is up regulated in transformed or infected cells while ligands for 
inhibitory receptors are polymorphic variants of MHC class I molecules expressed by all 
normal cells.  
Inhibitory receptors include killer immunoglobulin-like receptors (KIRs) in humans recog-
nizing subclasses of human leukocyte antigen (HLA)-A, -B and -C alleles; Ly49 C-type lectin 
superfamily receptors in mice and CD94/NKG2 (11) heterodimers specific for HLA-E in both 
species (12, 13). The engagement of inhibitory receptors leads to tyrosine phosphorylation of 
immune tyrosine-based inhibitory motifs (ITIM) that recruit tyrosine phosphatases such as 
SHP-1 (Src homology2 domain-containing phosphatase) and SHP-2, which suppress NK cell 
responses by dephosphorylating the protein substrates of the tyrosine kinases linked to acti-
vating receptors of NK cells (14).  
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Activating receptors consist of Ig superfamily members such as activating KIRs, CD16, 
CD2, 2B4 and the natural cytotoxicity receptors (NCR) NKp46, NKp30 and NKp44 and of 
member of the C-type lectin superfamily such as NKG2D. CD16, also known as FcRIII, 
represents a low affinity receptor for the Fc portion of antibodies belonging to the IgG isotype 
(15) and mediates antibody dependent cytotoxicity (ADCC), whereas natural cytotoxicity is 
mediated by NCRs, NKG2D, CD2 or 2B4 (16). Remarkably, human NK-cell subsets differ in 
their expression of NKRs (17, 18), suggesting unique regulation of cytotoxic properties. Thus, 
CD56bright NK cells do not express KIRs and have high-levels of CD94-NKG2A expression, 
whereas the opposite is the case for CD56dim NK cells (17, 18). Also CD16 is present on most 
of the CD56dim NK cells while 50-70% of CD56bright are negative for CD16 or express it at 
low density (10). In contrast, the activating receptor NKG2D and activating NCRs are equally 
expressed on both NK-cell subsets (19, 20).  
 
1.3.2 Cytokine and chemokine receptors and adhesion molecules 
All NK cells express the low-affinity interleukin-2 receptor (IL-2R), comprised by the IL-
2R and the IL-2Rchain. In addition, CD56bright NK cell are the only lymphocytes that con-
stitutively express the high-affinity heterotrimeric IL-2R (IL-2R) (21, 22). Consequently, 
this subset displays in vitro and in vivo a high proliferative response to low (picomolar) doses 
of IL-2 alone (23, 24). Furthermore, CD56bright NK cells, unlike CD56dim, express the receptor 
for stem cell factor (c-kit or CD117) and the alpha chain of the IL-7 receptor, whereas 
CD56dim do not. Both subsets of NK cells constitutively express several receptors for mono-
cyte-derived cytokines (monokines), including IL-1, IL-10, IL-12, IL-15 and IL-18 (19). For 
interleukin-18 receptor (IL-18R) and IL-1 receptor (IL-1R), higher expression levels have 
been shown in the CD56bright subset (25).  
NK cells express several chemokine receptors and again CD56bright and CD56dim NK cells 
display distinct repertoires of these receptors (8). So, CD56bright express secondary lymphoid 
organ (SLO) homing markers, namely CCR7, L-Selectin (CD62L) and CXCR3 (10, 19, 26), 
whereas CD56dim lack these receptors and therefore do not have the potential to migrate into 
SLO. The expression of SLO homing markers together with the constitutive expression of the 
high-affinity IL-2R highlights the possibility of cross-talk between CD56bright NK cells and T 
cells in SLO, since IL-2 is produced only by T and not by NK cells (10, 27). 
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In contrast, CD56dim lack CCR7 and CXCR3 expression and are mainly CD62L negative, but 
show high levels of CXCR1 and CX3CR1 expression, molecules important for migration to 
inflamed tissues (8). 
 
1.3.3 Functional responses 
NK cells can be activated in two ways. On the one hand, they proliferate and produce cy-
tokines in response to cytokine stimulation. On the other hand, they can be stimulated via en-
gagement of activating receptors, which results in cytotoxicity and cytokine production.  
Consistent with their expression of the high affinity IL-2R, the CD56bright NK-cell subset is 
able to proliferate in response to low doses of IL-2. On the contrary, CD56dim NK cells need 
much higher IL-2 concentrations for a significant proliferative response. IL-15, which acts via 
the IL-2/15R, can also stimulate proliferation of CD56bright and to lower degree of CD56dim 
NK cells (28). 
Due to the constitutive expression of for numerous monokine receptors, NK cells rapidly pro-
duce cytokines in response to stimulation by monokines (28-30). CD56bright are considered to 
be the primary source of NK-cell-derived cytokines, whereas the CD56dim NK-cells are poor 
cytokine producers following cytokine stimulation in vitro (10). This observation suggest that 
the major function of CD56bright NK cells during the innate immune response in vivo might be 
to provide macrophages and other APCs with early IFN-and other cytokines, promoting a 
positive cytokine feedback loop and efficient control of infection (10). 
Activation of NK-cell cytotoxicity is thought to be mediated by a balance of inhibitory and 
activating signals (Figure 1). As it could be expected by the higher expression levels of lytic 
granules in CD56dim NK cells, they are naturally more cytotoxic than CD56bright ones (8, 9). 
However, after activation with IL-2 or IL-12 in vitro, or following low dose therapy with IL-2 
in vivo, CD56bright and CD56dim cells have similar cytotoxic capacity (21, 22, 31). NK cells 
mediate ADCC also, which requires the activation and engagement of the FcRIII by Anti-
body-coated target cells (32). CD56dim, expressing high-levels of CD16, exhibit greater levels 
of ADCC compared to the CD56bright NK cells (33). 
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1.4 Mechanism of NK cell self tolerance 
 
NK cells were originally identified by their ability to spontaneously kill certain tumour tar-
get cells in vivo and in vitro without prior sensitization, if these tumour cells express low lev-
els of MHC class I molecules at their surface. MHC class I proteins can be down regulated in 
case of infection by viruses or malignancies as a mechanism to escape from the immune sys-
tem. In this case sensing lack of MHC class I on a target cells results in “missing-self” recog-
nition by NK cells (34). 
MHC class I-specific inhibitory receptors provide a molecular mechanism for missing-self 
recognition. Following inhibitory receptor engagement, NK cell cytotoxicity and cytokine 
production are inhibited or abrogated. However, inhibitory receptors do not play alone the 
decisive role in NK cell- target cell interaction. NK cells express activating receptors in addi-
tion and upregulation of ligands for these receptors on infected or transformed cells in some 
cases is sufficient to render a target cell sensitive to NK cell mediated killing, even if it ex-
presses a full set of MHC class I molecules. Thus, the balance between activating and inhibi-
tory signals the NK cell receives from a given target cell decides whether a NK cell becomes 
activated or not to produce inflammatory cytokines and/or kill the target cells (Figure 1), (12, 
13, 35). 
In general, each inhibitory receptor is expressed randomly by only a subset of NK cells. As 
a result, the NK cell population consists of many subpopulations expressing various combina-
tions of the available inhibitory receptors specific for distinct polymorphic variants of MHC 
class I molecules and consequently have a distinct pattern of reactivity. MHC class I mole-
cules show enormous allelic variations and individual inhibitory NK cell receptors bind cer-
tain MHC class I variants and not others. Since the genes for inhibitory receptors and their 
cognate MHC class I ligands are inherited independently, genetic mechanisms cannot ensure 
that each NK cell inhibitory receptor encounters its specific self-MHC class I molecule (36). 
In line with this fact, some NK cells exist which do not express any self-MHC class I specific 
inhibitory receptor. Because such cells are potentially autoreactive, developmental processes 
must exist that either repress the activity of such cells or prevent them from developing or 
maturing in the first place. 
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Recent studies have shown that such NK cells are hyporesponsive after engagement of ac-
tivating receptors and therefore self tolerant. Conversely, NK cells, which express inhibitory 
receptors for self-MHC, are functionally competent (37, 38). Thus, in humans, it has been 
shown that KIR2DL2/L3+, KIR2DL1+ or KIR3DL1+ CD56dim NK cells derived from donors 
expressing the corresponding HLA class I ligands (group C1 alleles, group C2 alleles, and 
HLA allotypes with the Bw4 epitope, respectively) are more responsive to CD16 cross-
linking and stimulation with class I negative target cells than other NK cell subsets (39, 40). 
These data imply that expression of self-specific inhibitory receptors is a crucial event during 
NK cell education and determines whether a cell will end up in the pool of competent or hy-
poresponsive NK cells. However, the mechanisms underlying NK cell education, are still con-
troversially debated (Figure 3). On the one hand, it has been proposed that engagement of 
self-MHC specific inhibitory receptors directly confers functionality to NK cells, a process 
which is referred to as “licensing” (38, 41). Alternatively, it has been suggested that hypore-
sponsiveness of NK cells lacking self-specific inhibitory receptors is a consequence of persis-
tent stimulation that is not counterbalanced by inhibitory signals. In this model, potentially 
autoreactive NK cells would be silenced by the lack of inhibition (“disarming model”) (4, 38, 
41, 42).  
 
Introduction  12 
 
 
Figure 3: Mechanisms of NK cell tolerance 
(a) In the arming model, positive signals received by a precursor (immature) NK cell through interac-
tions with MHC-class-I-expressing target cells are required to induce functional competence ('arming') 
of the cell (b) In the disarming model, NK cells express stimulatory and inhibitory receptors. NK cells 
in which inhibitory and stimulatory signals are balanced are allowed to retain (or acquire) responsive-
ness. NK cells that receive unopposed positive signals (for example, in an MHC-class-I-deficient host) 
are 'disarmed' and thereby rendered unresponsive. NK cells could be disarmed during their develop-
ment or in response to chronic positive signaling. Figure adapted from Raulet et al (4). 
 
Moreover, it is still unclear whether the hyporesponsive phenotype is stable or whether it is 
contextual, meaning that it can be reversed in certain contexts (Figure 4). Indeed, during in-
fection with Listeria monocytogenes, NK cells that lack inhibitory receptors for self-MHC can 
produce as much IFN- as competent NK cells (37). Interestingly, NK cells derived from 2-
microglobulin deficient mice, which are hyporesponsive after certain activating stimuli, are 
still able to control cytomegalovirus infection in vivo (43). 
Introduction  13 
 
 
Figure 4: Contextual hyporesponsiveness 
Depicted are the outcomes of interactions between uninfected target cells (a) or infected target cells 
(b) and responsive (left) or hyporesponsive (right) NK-cell subsets. The responsive NK cells express a 
self-MHC-class-I-specific inhibitory receptor, whereas the hyporesponsive NK cells do not. The hy-
poresponsive cells do not respond to target cells with decreased expression of MHC class I molecules 
but can respond to cells with increased expression of stimulatory ligands. Figure adapted from Raulet 
et al (4). 
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1.5 NK subset development 
 
While it is clear that NK cells are part of the hematopoietic system and are derived from 
CD34+ hematopoietic progenitor cells (HPCs) (44-46), less is known about the sites of devel-
opment and details of this process. Yet, several studies indicate that both lymph nodes and 
bone marrow (BM) may be important.  
Thus, bone marrow ablation in mice had an adverse effect on NK cell development relative 
to other hematopoetic lineages. Moreover, IL-15 which has been identified to be the crucial 
cytokine for NK cell development and maintenance in humans and mice, is expressed by pri-
mary bone marrow stromal cells and culture of human bone marrow derived HPCs in IL-2 or 
IL-15 results in the generation of CD56bright NK cells (47). Two additional BM stromal fac-
tors, ligands for the receptor tyrosine kinases c-kit and flt-3, have also been shown to act syn-
ergistically with IL-15 to enhance NK cell expansion in culture (48).  
Nonetheless, NK development might not occur completely in the bone marrow, since 
CD56bright NK cells are enriched in all secondary lymphoid organs compared to CD56dim 
which are mainly found in bone marrow and blood (49, 50). Like PB-CD56bright NK cells, 
SLO-NK cells exhibit no KIR or CD16 expression and poor cytolytic activity. Therefore, it 
has been postulated that this SLO-CD56bright NK population was less mature than the PB-
CD56dim subset (51). Furthermore, CD34+ CD45RA+ pre-NK cells present at low frequencies 
in BM and in blood were found to be enriched highly and selectively in SLO (52). This en-
richment of both pre-NK cells and CD56bright NK cells within SLO relative to BM or blood, 
together with the presence of DCs capable to trans-present IL-15, suggest that SLO may be 
another site for NK-cell development in vivo (53). Indeed, phenotypically and functionally 
distinct cell populations that represent stages along the NK- cell developmental pathway from 
CD34+ CD45RA+ HPCs to CD3CD56bright NK cells were discovered in situ (54, 55).  
With its higher intrinsic cytotoxicity, more abundant expression of CD16 and lower prolif-
erative response, CD56dim NK cells appears to be more terminally differentiated than 
CD56bright NK cells. The facts that in vivo therapy with IL-2 generates a predominance of 
CD56bright NK cells (24) and that this subset is the first one reoccurring after bone marrow 
transplantation (56) promote the hypothesis that CD56dim cells derive from CD56bright ones in 
the periphery (10).  
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In this regard, controversial hypothesis have been proposed for the developmental relation-
ship between these two NK cell subset, since CD56bright NK cells have been suggested to rep-
resent either precursors of CD56dim cells or to be derived from CD56dim cells (Figure 5) (51, 
55, 57-59). Studies addressing this question have been hampered by the lack of CD56 in mice, 
by missing informations regarding the site of terminal NK cell differentiation and by the lack 
of markers, which together with CD56 expression would identify NK cell subsets with inter-
mediate phenotype and functional properties. 
 
Figure 5: Human NK-cell subset development 
NK-cell development can be divided into three discrete stages based on in vitro models: CD34+ NK-
cell progenitor, responsive to flt3 ligand (FL) and/or c-kit ligand (KL) differentiates into a CD34+ in-
terleukin-15 receptor (IL-15R)+ NK precursor which then differentiates into a functionally mature 
CD56bright NK cell. The developmental relationship between CD56bright and CD56dim NK cells has 
never been established definitively, and CD56dim NK cells have not been generated in vitro. Either 
CD56dim NK cells could develop from a unique CD56dim NK-cell precursor or an alternate signal (e.g. 
a novel cytokine) could induce the differentiation of CD56dim cells from a common NK-cell precursor 
or CD56bright cells could maturate into CD56dim NK cells. Figure adapted from Cooper et al (10). 
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1.5.1 Heterogeneity of CD56dim NK cells 
Besides the division of labour between CD56bright and CD56dim NK cells, in the last years it 
became clear that CD56dim NK cells themselves do not represent a homogenous population of 
effectors ready to proliferate, to produce cytokines or to kill. In contrast, NK cells undergo a 
differentiation program which includes MHC-dependent education (37-39), priming (60-62) 
and even generation of memory during recall responses (63, 64). This complexity implies the 
existence of intermediate stages of NK cell differentiation, which can guarantee an efficient 
division of labour as it has been shown for cells of the adaptive immune system. Interestingly, 
CD56dim NK cells are heterogeneous concerning the expression of several markers, namely 
KIR, NKG2A, CD27 and CD62L. It has been shown that among CD56dim cells, competent or 
hyporesponsive NK cells can be identified according to the expression of MHC specific in-
hibitory receptors such as KIR or NKG2A. On the other hand, it is reported that also CD27 
expression influences NK cell functions as it correlates with high ability to proliferate and to 
produce IFN-and with low cytotoxic potential, at least in humans (65, 66). However, func-
tional analysis considering all these molecules together including CD62L has never been per-
formed so far. 
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2 Aims of the Thesis 
 
Human NK cells can be divided into CD56bright CD16- KIR- CD62L+ and CD56dim CD16+ 
KIR+/- CD62L+/- subsets that differ in function, phenotype and tissue localization. While 
CD56bright NK cells are characterized by the ability to proliferate extensively and to produce 
IFN- in response to cytokines, CD56dim NK cells have high cytotoxic capacity. Nonetheless, 
the developmental relationship between these two NK cell subsets remains controversial. 
CD56bright NK cells have been suggested either to be precursors of CD56dim cells or to derive 
from CD56dim cells. 
Interestingly, CD56dim NK cells themselves do not represent a homogeneous population 
concerning the expression of several surface molecules, such as inhibitory receptors, CD62L 
or CD27 and concerning functional properties. Thus, the expression of at least one self-MHC 
specific inhibitory receptor correlates with higher ability to kill and to produce IFN- in re-
sponse to stimulation via activating receptors. Engagement of inhibitory receptors by cognate 
MHC molecules is the mechanism by which NK cells mediate tolerance towards self and ac-
quisition of inhibitory receptors by NK cells is a critical prerequisite for the generation of 
functional competent NK cells. Whether or not hyporesponsiveness of NK cells can be over-
come under certain circumstances is not known so far. In addition to inhibitory receptors other 
molecules, such as CD27, which has been correlated with high ability to proliferate and to 
produce IFN-, or CD62L, a lymph node homing marker, are differentially expressed within 
CD56dim NK cells. Both of them are commonly used to identify distinct T cell maturation 
stages 
The aim of this thesis was to investigate whether PB-CD56bright NK cells can differentiate 
in vitro and in vivo to cells analogous of CD56dim NK cells and whether SLO can be sites of 
NK cell maturation. Moreover, it was analysed whether cytokines can induce expression of 
self specific inhibitory receptors and if so whether that would be sufficient to educate hypore-
sponsive NK cells to become competent and self tolerant. The aim of the third part of my the-
sis was to evaluate whether the expression of CD62L or other markers might be used to iden-
tify intermediate stages of NK cell maturation characterized by distinct functional properties 
and in line with that better define NK cell developmental history. 
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3 Materials and Methods 
 
3.1 Buffers, Medias and solutions 
 
Table 1: Buffers, Media and solutions 
Buffer Description and company 
PBS-buffer  
(Phosphat-buffered Saline) 
1,5 mM KH2PO4 
2,7 mM KCL 
8,1 mM Na2HPO4 
137 mM NaCL  
pH: 7,2- 7,4 
PBS/BSA-buffer: 
 
5g/l (0,5%) Bovine serum albumin (BSA Boehringer-
Mannheim, Germany) in PBS-buffer 
PBS/BSA/EDTA 
 
2 mM ethylene diaminetetraacetic acid (EDTA) in PBS/BSA 
buffer 
RMPI medium: 
 
Rosewell Park Memorial Institute Medium (RPMI) 1640 
(Gibco BRL, USA), supplemented with 100 U/mL penicillin 
and 0.1 mg/ml streptomycin and either  
10% human AB serum (Lonza, USA) or  
10% foetal calf serum (FCD, Sigma Aldrich, Germany) 
Ficoll: Lymphocyte-Separations-Medium (Ficoll-PaqueTM PLUS Am-
ersham Pharmacia Biotech AB, Sweden) 
FACS-Perm2: FACSTM -Perm-Solution (BD), diluted 1:10 in Aqua dest 
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3.2 Devices and materials 
 
Table 2: Devices and material 
Device or material Description and company 
FACS-tubes Falcon 5ml, round bottom (BD Bioscience) 
Reaction tubes Safe-Lock-Tubes 0,5ml; 1,5ml; 2ml  
(Eppendorf) 
Cell filter CellTrics 30 μm, (Partec, Germany) 
Lamina flow box HERA safe (Heraeus, Germany) 
Flow Cytometer FACS LSRII (BD Bioscience) 
FACS (Cell-Sorter) FACSAria (BD) 
FACSDiva (BD) 
MACS (Cell-Sorter) AutoMACS (Miltenyi Biotec) 
Centrifuges Multifuge 3 S-R (Heraeus, Germany) 
Biofuge fresco (Heraeus, Germany 
Megafuge 1.0 (Heraeus, Germany) 
Cell Counter Casy DT (Schärfe Systems, Germany) 
Incubator Cell culture incubator (Heraeus, Deutschland) 
96-er Microtiterplates (round bottom) Greiner Bio-one PS-Microplate 96K (ELISA) 
Software FlowJo (Tree Star Inc.) 
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3.3 Chemicals
 
Table 3: Chemicals 
Chemical Company 
Brefeldin A (Bref-A) 
(5mg/ml in 70% ethanol) 
Sigma-Aldrich, Germany 
Carboxyfluoresceindiacetat (CFDA) 
5mM in Dimethylsulfoxid (DMSO) 
Molecular Probes, Netherlands 
Monensin BD Bioscience, Germany 
EDTA  
(2mM in PBS-Buffer) 
Merck, Germany 
4,6-Diamidin-2-Phenylindol-Dihydrochlorid 
(DAPI) 
 (1g/ml in PBS-Buffer) 
Roche, Germany 
Streptavidine (SA)-Pacific Blue 
SA-Alexa 647 
SA-PE 
Molecular Probes 
 
3.4 Cell culture conditions 
 
All experimental procedures were performed under sterile conditions in a Laminar-Flow-
Box (HERA safe, Heraeus, Germany).  
5x105/ml primary human cells were cultured in RPMI medium with 10% AB serum in 96-
well round bottom plates (Greiner bio-one, Germany) at 37°C and 5% CO2 in a cell culture 
incubator (Heraeus, Germany). Tumour cell lines were cultured in RPMI medium with 10% 
FCS in 10 ml cell culture flasks (Cellstar, Greiner bio-one, Germany) under the same condi-
tions. 
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Cell counts were calculated with a Casy DT cell counter (Schärfe Systems, Germany) ac-
cording to manufacturer’s instructions. 
 
3.5 Cell isolation and cytometric analysis 
 
3.5.1 Isolation of Peripheral blood mononuclear cells (PBMC) 
Whole blood contains erythrocytes, granulocytes, PBMC, which comprise lymphocytes (B 
cells, T cells and NK cells), monocytes and dendritic cells. PBMC can be separated from 
erythrocytes, granulocytes and plasma by density gradient centrifugation with Ficoll, a neu-
tral, highly branched, hydrophilic polysaccharide (p=1.07 g/l). Ficoll has lower density than 
erythrocytes and dead cells, the same as granulocytes and higher ones than mononuclear cells. 
After density gradient centrifugation, typical layers formed from top to bottom are plasma, 
PBMC, Ficoll and granulocytes, and erythrocytes, which are present in pellet form. 
For PBMC isolation, Buffy Coats were obtained from healthy donors after donor informed 
consent and approval by the local ethics committees on human studies (Charité, Berlin, Ger-
many). Blood samples were diluted 1:1 in PBS/BSA and piled up carefully on three 50 ml 
tubes (BD, Germany) containing 12.5 ml Ficoll-Paque. The samples were centrifuged at 800x 
g for 20 min at room temperature in a Multifuge centrifuge (Heraeus, Germany) without 
brake. The upper plasma layer was removed until 1 ml above the typical white layer contain-
ing the PBMC. PBMC were transferred into new 50 ml tubes; these were filled up with 
PBS/BSA and centrifuged at 300x g for 10 min at 4°C. The supernatant was discarded and the 
second washing step was performed at 175x g for 15 min in order to remove thrombocytes. 
After discarding the supernatant, cells were used for further experiments. 
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3.5.2 Magnetic activated cell sorting (MACS®)
For enrichment and isolation of cell populations, Magnetic cell separation was employed. 
The MACS® technology (Miltenyi Biotec GmbH, Germany) is based on the labelling of cell 
surface molecules with antibodies coupled to superparamagnetic particles of approximately 
50nm in diameter („Microbeads“) and uses MACS® Columns for cell separation. These col-
umns are placed in a strong permanent magnet (MACS® Separator) and a high-gradient mag-
netic field is induced on the column matrix. The cell suspension containing labelled and unla-
belled cells is placed on the column, and while unlabelled cells pass through and can be 
collected as negative fraction, labelled cells are bound to the matrix and are released after re-
moval of the column from the magnet as positive fraction. Thus, MACS® Technology can be 
used for enrichment or isolation (positive selection) or depletion (negative selection) of cells. 
The cells of interest can be labelled either directly with antibodies coupled to magnetic beads 
or indirectly by labelling the cells first with a primary antibody and subsequently with a sec-
ondary antibody directed against the isotype of the primary antibody or the fluorochrome, 
which is coupled to the primary antibody. 
For pre-enrichment of human total NK cells, 1x109 PBMCs were incubated with CD56 
MicroBeads (Miltenyi Biotech, Germany) and subsequent positive selected using the 
Automacs Separator (Miltenyi Biotech, Germany). For some experiments, NK cells were en-
riched by negative selection using NK cell isolation Kit II from Miltenyi, a so called “un-
touched sort”, where all cells apart from NK cells are magnetically labelled and depleted.  
For isolation of circulating myeloid dendritic cells (mDCs), PBMCs were first stained with 
anti-CD1c-FITC antibodies and were subsequently sorted using anti-Fitc MicroBeads 
(Miltenyi Biotech, Germany) (Staining protocol see 2.4.3).  
CD4+ T cells were enriched after staining of PBMCs with CD4 Microbeads followed by 
positive selection with the Automacs.  
Briefly, 1x109cells/ml were incubated for 15min at 4°C with the respective beads added at a 
final dilution of 1:5 in PBS/BSA/EDTA. All washing steps were performed at 300 x g and 4°C 
for 10min using PBS/BSA/EDTA. Before MACS, cells were pre-separated (30μm filter, 
Partec, Germany) in order to protect MACS columns from plugging. Cells were separated 
using the Automacs program possel_s (positive selection in sensitive mode), a program ap-
plied for the enrichment of rare cell populations. This program facilitates high recovery of 
cells, although with lower purity. In case of the negative selection, NK cells are found in the 
flow through. All reagents used for MACS are depicted in Table 4. 
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Table 4: MACS reagents 
-CD56 Microbeads Miltenyi Biotec 
-CD1c Fitc Miltenyi Biotec 
-Fitc Microbeads Miltenyi Biotec  
NK cell isolation Kit II  Miltenyi Biotec 
-CD4 Microbeads Miltenyi Biotec 
 
3.5.3 Fluorescence Activated Cell Sorting (FACS) and flow cytometric analysis 
Flow cytometry developed from fluorescent microscopy where cell surface molecules are 
labelled with monoclonal antibodies coupled to fluorescent dyes. With the help of this 
method, surface and intracellular molecules can be detected. Immunofluorescence staining 
can be employed either to analyse cells using flow cytometry or to sort cell populations with 
FACS.  
The principle underlying single cell analysis is hydrodynamic focussing of the cells in sus-
pension. One cell at a time is passing a capillary and the fluorochome coupled to the antibody 
used for staining becomes excited by a laser beam. At present four different lasers, blue-, red-, 
violet and UV-laser, are used in one analyser. In order to determine the relative size of the 
cells, forward scattered light (FSC) is detected from the opposite site of the illuminating light. 
In an angle of 90°C side scatter (SSC) and the emission wavelengths of the excited fluores-
cent dyes are detected. The side scatter provides information on the granularity of cells.  
Once a fluorochrome becomes excited with the defined wavelength of the laser, the emitted 
light is collected and passes long pass filters, which reflect all the wavelengths shorter than 
the indicated one. Afterwards the transmitted light passes band pass filters that allow trans-
mission of a certain area of wavelengths and thus fine-tune the spectral wavelengths that are 
finally detected. In the end, the signal hits the photomultiplier, becomes amplified 1000 to 1 
million folds depending on the supplied voltage, is converted into electrical current pulses and 
detected (Radbruch, Flow cytometry and cell sorting 2nd Ed.). 
Cells cannot only be analysed, but they can as well be sorted according to differential 
marker expression using high voltage deflection plates, which deflect side streams during sort-
ing.  
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Although many different fluorescent dyes with distinct excitation and emission spectra are 
available, the emission spectra of some fluorochromes partly overlap, leading to the detection 
of one dye in more than one detector. In order to overcome this inconvenience, compensation 
is required. 
The configuration of long pass and band pass filters and the corresponding fluorescent dyes 
used in this study are summarized in Table 5. 
 
Table 5: Fluorochromes and filter sets 
Fluorochrom Laser  Longpass-Filter Bandpassfilter 
FITC 488-nm blue Laser 505 530/30 
PE  488-nm blue Laser 550 575/26 
PerCp 488-nm blue Laser 635 670/14 
PE-Cy7 488-nm blue Laser 735  780/60 
Pacific Blue; 
DAPI 
405-nm violet Laser - 440/40 
APC  
Cy5  
Alexa 647 
633-nm red Laser - 660/20 
APC-Cy7 633-nm red Laser 680 680/30 
 
In order to obtain high purity sorting of different cell subsets, MACS enriched cell frac-
tions were stained with mouse-anti-human monoclonal antibodies either coupled to fluores-
cent dyes or to biotin, which in a second step can be labelled with a streptavidin-dye conju-
gate.  
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In Table 6, all antibodies used in the experiments are listed. “2D KIR” includes 
KIR2DL1/S1/L2/S2/L3, “3D KIR” includes KIR3DL1/S1/L2 and “2+3DKIR” the combina-
tion of 2D KIR and 3D KIR. 
 
Table 6: Antibodies  
Antibody
(mouse-anti-human) 
Label Clone Company 
-CD56 PE-Cy7 
PE 
APC 
NCAM16.2 
 
BD Bioscience 
Miltenyi Biotec 
Miltenyi Biotec 
-CD3 Fitc  
Cy5 
UCHT-1 DRFZ 
-CD3 PerCP UCHT-1 Biolegend 
-KIR3DL1 
 
PE 
     PE 
DX9 
 
Biolegend 
    Miltenyi Biotec 
-KIR2DL1/S1 Cy5  
biotin 
EB6 DRFZ 
-KIR2DL2/L3/S2 Cy5 
biotin 
GL183 DRFZ 
-KIR3DL1/ L2/S1 Cy5  
biotin 
AZZ158 DRFZ 
-CD62L 
     -CD62L 
PE 
Fitc 
APC 
Dreg 56 
    Dreg 56 
BD Bioscience 
    BD Bioscience 
-NKG2A Cy5 
biotin 
Z270 DRFZ 
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-CD107a Fitc 1D4B BD Bioscience 
-BW4 Fitc 0.L.6 USBiological 
-CD19 APC 1D3 BD 
-CD14 Cy5 TM1 DRFZ 
-CD4 PerCp TT1 DRFZ 
 CD27 PE 
Cy5 
2E4 DRFZ 
 CD69 Fitc L78 BD Bioscience 
-CD127 PE R34.34 Beckman Coulter 
-NKp46 PE 9E2 Miltenyi Biotec 
-NKp30 APC 2.29 Miltenyi Biotec 
-NKG2D APC BAT221 Miltenyi Biotec 
-CCR7 PE 
     Fitc 
150503 R&D System 
-IgG2a biotin  Southern Biotech 
-CD45RA PE-Cy7 L48 BD Pharmingen 
-CD45RO Fitc UCHL1 BD Pharmingen 
-CXCR3 APC 1C6 BD Pharmingen 
-CD117 APC YB5.B8 BD Pharmingen 
-CD16 PE 
APC-Cy7 
3G8 BD Pharmingen 
-granzymeA PE CB9 BD Pharmingen 
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-granzymeB Alexa Fluor 647 GB11 BD Pharmingen 
-granzymeB PE GB12 Caltag 
-perforin APC dG9 Biolegend 
-Ki67 Fitc 35/Ki67 BD Bioscience 
-IFN APC 
Fitc 
B27 
4SB3 
BD Pharmingen  
      DRFZ 
TNF FITC MabII BD Pharmingen 
-IL-15R Biotin JM7A4 Biolegend 
-CD122 PE Mik-3 BD Pharmingen 
-CD132 Biotin TUGm2 BD Pharmingen 
-STAT5 (pY694) Alexa-Fluor 647 47 BD Pharmingen 
CXCR1 APC  BD Pharmingen 
 
Up to 1x107cells/100μl were stained in the dark for 10min on ice (in case of intracellular 
staining for 20min at room temperature) and afterwards washed with PBS/BSA. Propidium 
iodide (PI) or DAPI, which intercalates the DNA of dead cells, was added to the cells before 
sorting or analyzing them in order to exclude non-viable cells (not when cells were fixed for 
intracellular staining). Cells were sorted using a FACSAria cell sorter (BD Biosciences, USA) 
or analysed at the LSRIITM flow cytometer employing FACSDiva Software (BD Bioscience). 
Data were analysed using FlowJo software (Tree Star, Inc). 
In order to obtain highly purified NK cell subsets, MACS-enriched CD56+ cells from PB 
or Lymph nodes (LN) were FACS-sorted according to the lack of CD3 and the expression of 
CD56 and additional markers, when indicated in the text. Histological evaluation of LN was 
performed by Guido Ferlazzo (University of Messina, Italy). 
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Briefly, LN were incised immediately after removal and cut into two parts, one of which 
was paraffin embedded in order to perform histology, while the other was processed for single 
cell isolation. For isolation of LN single cells, LN were mechanically dissociated and then 
treated with enzymes, as previously described (50). 
For FACS sorting of highly purified mDC, MACS enriched CD1c-Fitc+ fraction was fur-
ther stained with anti-CD19-APC and anti-CD14-Cy5 in order to exclude contamination of B 
cells or monocytes.  
Naive and memory T cells were isolated after positive selection of CD4 cells by MACS 
followed by FACS sort after staining with anti-CD4, anti-CD45RA, anti-CD45RO and anti-
CD27mAbs. 
Purity of all sorted subsets was always above 98%. 
 
3.6 NK cell stimulation 
 
3.6.1 Proliferation assay 
CFDA labelling: up to 1x107 cells/ml were incubated with 0.5M CFDA in PBS for 4 min-
utes at room temperature in the dark. Reaction was stopped by filling up the tube with RPMI 
medium plus 10% AB serum and cells were washed twice. 
For analysis of proliferative capacity CFSE labelled NK cells were stimulated for 5 days in 
the presence of 50ng/ml IL-2 or 50ng/ml IL-15 (R&D) or 50ng/ml IL-12 (Miltenyi Biotec) or 
together with 2x104 PB-derived mDCs plus 10g/ml R848 (Alexis Biochemicals) and 
100ng/ml LPS (E.coli R515, Ligands set I, Apotech). 
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3.6.2 Analysis of cytokine production 
To analyse IFN- production, NK cells were stimulated in the presence of 50ng/ml IL-12 
and 50ng/ml IL-18 (Miltenyi biotec) for 28h. 10μg/ml BrefeldinA (Sigma-Aldrich) was added 
for the last 8 hours. Afterwards cells were fixed by incubation for 10 minutes in a 1,5% for-
maldehyde (Merck) solution in PBS at room temperature. Following washing with PBS cells 
were permeabilised with FACSPerm Solution (BD) according to the manufactures’ instruction 
and stained with anti-IFN-mAbs for 20min at room temperature. IFN- expression was ana-
lysed at the LSRII. In some experiments, additional surface markers were stained before fixa-
tion and permeabilisation. 
 
3.6.3 Stimulation via activating receptors 
To analyse IFN- and TNF expression after activating receptor stimulation, goat F(ab)2 
anti-mouse IgG (Beckman Coulter) was coated to plastic wells (96 well, PS, U-Bottom, 
greiner bio-one) for 2 hr in PBS at 37°C at 20 μg/ml. After washes, mouse anti-human NKp30 
(AZ20), NKp46 (BAB281), NKG2D (BAT221), 2B4 (PP35) and CD2 (PPA-2.10) specific 
mAb (kindly provided by S. Parolini, University of Brescia, Italy), were incubated for 30 min 
at 4°C at 10 μg/ml in PBS. After washes, 2x105 cells/well were plated in each well and stimu-
lated for 8h in the presence of BrefeldinA.  
 
3.7 Analysis of cytotoxic potential 
 
NK cell cytotoxicity was analysed by cocultivating the indicated NK cell subset with the 
MHC-class I negative target cell line K562 (ATTC) or when indicated with 721.221, or 
721.221 transfectans expressing HLA-B51 or HLA-B7, in an effector to target ratio of 5:1 for 
6 h at 37°C.  
To measure degranulation as marker for cytotoxic potential the CD107a Mobilization assay 
was performed, as previously described (67). Briefly, NK cells were stimulated with the target 
cell line as described above in the presence of anti-CD107a FITC mAb (BD Pharmingen), 
0.7μl/ml Monensin (BD Bioscience) and 10g/ml BrefeldinA. Cells were subsequently 
stained for surface markers and analysed by flow cytometry.  
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In some experiments cytotoxicity was directly assessed using a flow cytometric assay for 
NK cell killing developed by McGinnes et al with slight modifications (68). Briefly, K562 
cells were loaded with 5 M CFDA for 4 min, washed twice and incubated with NK cells. 
After 6 h each sample was resuspended in a final volume of 250 l of PBS, to which 
propidium iode was added. Live target cells were identified by strong green fluorescence 
whereas dead target sells (Td) showed slightly reduced green and red fluorescence. Specific 
lysis was calculated as:  
Td (cultured with effector cells) -Td (cultured without effector cells). 
 
3.8 Analysis of telomere length and telomerase activity 
 
The indicated NK cell or T cell subsets were sorted from PB as described in 2.4.3, stored in 
90% FCS/ 10% DMSO at -80°C and send for analysis of telomere length to Guido Ferlazzo 
(University of Messina, Italy). 
LNs were obtained from cancer patients undergoing surgical resection. 
Analysis of telomere length was performed using a quantitative fluorescence in situ hy-
bridization methodology (Flow-FISH) that employs a fluorescein-conjugated peptide nucleic 
acid (PNA) probe (Telomere PNA Kit/FITC for Flow Cytometry, DakoCytomation, Den-
mark), according to manufacturer instructions. Briefly, a single cell suspension of sorted NK 
cells was mixed with control cells (i. e. the 1301 cell line) which display very long telomeres. 
Mixed cell suspension DNA was denatured for 10 minutes at 82° C either in hybridization 
solution without probe or in hybridization solution containing fluorescein-conjugated PNA 
telomere probe. Hybridization took place in the dark at room temperature overnight and was 
followed by two washes at 40°C. After propidium iodide staining, flow cytometric analysis 
was performed gating on G0/1-cells. The relative telomere length (RTL) value was calculated 
as the ratio between the telomere signal of each sample and the control cells (1301 cell line) 
with correction for the DNA index of G0/1 cells. This correction was performed in order to 
standardize the number of telomere ends per cell and thereby telomere length per chromo-
some.  
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3.9 RT-PCR analysis of KIR transcripts 
 
Total RNA was extracted from CD56bright, CD56dim KIR- and CD56dim KIR+ NK cells at 
day 0 directly after sorting or after 5 days of culture in the presence of IL-2 using RNeasy 
micro kit (Qiagen) according to manufacturer’s instruction. RNA was send to Michela Falco 
(Institutio Giannina Gaslini, Genoa, Italy) for RT-PCR analysis of KIR transcripts. 
cDNA synthesis was performed on about 500 ng of RNA using oligo (dT) primers. Three 
different sets of primers were used in this study. KIR up: CAT GTY GCT CAY KGT CGT C 
and KIR down: GGT TTT GAG ACA GGG CTG allowed the amplification of the KIR2DL1, 
KIR2DL2, KIR2DL3, KIR2DL5, KIR3DL1, KIR3DL2, KIR2DS1, KIR2DS2, KIR2DS3, 
KIR2DS4, KIR2DS5 and KIR3DS1 ORF. The sets of primers common up/C and common 
up/E allowed the amplification of a segment of activating and inhibitory KIR transcripts re-
spectively, as previously described (69). The PCR products were resolved into 0.8% agarose 
gel. 
 
3.10 Blood samples and Ethical applications 
 
Whole blood and leukocyte concentrates were collected from healthy donors. LN, thoracic 
duct lymph and blood were obtained from patients who underwent surgery for cancer resec-
tion. All sample collections were obtained after donor informed consent and approval by our 
Institutional Ethics Committee. 
For the vaccination study, 8 healthy donors aged 22-53 years without previous yellow fever 
vaccination or known exposure have been immunized once with YFV 17D (Sanofi Pasteur). 
Immediately before (day 0) and at day 7 and day 28 after vaccination 20 ml of blood has been 
drawn and analysed. 
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3.11 Statistical analysis 
 
If variables were not Gaussian distributed, Wilcoxon signed rank test was used for statisti-
cal analysis. For Gaussian distributed variables, paired student’s t test was used for statistical 
analysis. Gaussian distribution was tested by Shapiro Wilk normality test and D'Agostino & 
Pearson omnibus normality test. Linear correlation was analysed using the Pearson correlation 
coefficient. The test used for the individual experiments are indicated in the figure legends.
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4 Results
 
4.1 CD56bright NK cells display longer telomeres and acquire features of CD56dim
NK cells upon cytokine activation
 
The developmental relationship between CD56bright and CD56dim NK cells is still contro-
versially discussed in the literature. The aim of the first part of this thesis was to investigate 
whether peripheral blood (PB)- CD56bright NK cells are precursors of and therefore give rise to 
cells akin of CD56dim NK cells and whether secondary lymphoid organs can be sites of NK 
cell maturation. 
 
4.1.1 Phenotype of peripheral blood NK cells 
Many molecules have been described to be expressed differentially in PB-CD56bright and 
CD56dim NK cells. As shown in Figure 1 and described in several reports, the majority of PB-
NK cells ( 95%) belong to the CD56dim CD16+ NK subset and express lytic granules such as 
granzyme A (granzA), granzyme B (granzB) and CD16, the Fc receptor IIIA. The remaining 
PB-NK cells ( 5%) are represented by CD56bright CD16- cells (10), which conversely express 
very low levels of lytic granules and, unlike CD56dim, the receptor for stem cell factor (c-kit or 
CD117), the alpha chain of the IL-7 receptor and secondary lymphoid organ (SLO) homing 
markers, namely CCR7, CD62L and CXCR3. Notably, the MHC class I allele-specific Killer 
Ig-like receptors (KIR) are expressed on a considerable fraction of CD56dim CD16+ NK cells, 
while the CD56bright CD16- NK subset lacks KIR.  
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Figure 1: Phenotype of PB- NK cell subsets 
PBMCs were stained for CD3 and CD56 to gate on NK cells, and in addition for IL7R, c-kit, 
CXCR3, CCR7, CD62L, granzyme A (granzA), granzyme B (granzB), CD16 or 2+3D KIRs (KIR) and 
analysed by flow cytometry. Expression of these molecules in relation to CD56 density on CD3- 
CD56+ NK cells is shown. 
 
4.1.2 CD56bright NK cells derived from Peripheral blood and Lymph nodes display longer 
telomeres than PB-CD56dim NK cells 
CD56bright NK cells display a more immature phenotype compared to CD56dim NK cells in 
many functional aspects, such as proliferative capacity, ability to produce cytokines and cyto-
toxic potential (50, 55, 70). To investigate whether CD56bright NK cells represent an earlier 
step of NK cell differentiation than CD56dim ones, telomere length in NK cell subsets isolated 
ex vivo from PB and LN were evaluated. The measurement of telomere length has been 
widely employed to assess the proliferative history of distinct cell subsets, among which are 
naïve and memory T cells (71-76). In most normal somatic cells, telomeres sequences are lost 
during DNA replication and therefore telomere length inversely correlates with cell age. 
Analysis of telomere length was performed in cooperation with Barbara Morandi and Guido 
Ferlazzo from the Department of Human Pathology, School of Medicine at the University of 
Messina in Italy.  
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As shown in Figure 2, sorted PB-CD56dim NK cells displayed significantly shorter te-
lomere length than PB-CD56bright NK cells from the same donors (p  0.01), with a mean te-
lomere shortening of 15.3 % in the CD56dim compared to the CD56bright NK cells (Figure 2 B). 
For comparison, telomere length difference in naïve CD45RA+ CD45RO- CD27+ and memory 
CD45RA- CD45RO+ CD4+ T cells derived from PB of the same donors were calculated (Fig-
ure 2 C). It could be shown that telomere shortening in CD56dim compared to CD56bright NK 
cells (24.3 % and 15.4 %, respectively) correspond with the one observed in memory com-
pared to naïve CD4+ T cells. Notably, CD56bright NK cells displayed relative telomere length 
similar to naïve T cells, while CD56dim NK cells to memory T cells. In addition, comparative 
analysis of telomere length in PB-CD56dim NK cells and autologous LN-NK cells, which are 
predominantly CD56bright, revealed that PB-CD56dim NK cells exhibited significantly shorter 
telomeres than LN-NK cells (p  0.04), with a mean telomere shortening of 14.5 % in the PB-
CD56dim compared to the LN-CD56bright NK cells (Figure 2 D). A similar degree of telomere 
length reduction was observed when LN-NK cells were sorted and cultured for as long as 3 
weeks in the presence of 50ng/ml of IL-2, a cytokine that induces extensive NK cell prolifera-
tion (Figure 2 E). To exclude putative different ability in telomere maintenance between the 
two cell subsets being the reason for the observed differences in telomere length, telomerase 
activity was determined in highly purified CD56bright or CD56dim NK cells. Yet, the analysis of 
enzyme basal activity in PB-NK cells derived from three distinct donors did not show any 
difference between the two cell subset (data not shown) (77). 
In total, these data indicate that CD56bright NK cells have undergone a significant smaller 
number of cell divisions in vivo as compared to CD56dim and might therefore represent an 
upstream developmental stage of NK cells. 
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Figure 2: PB-CD56bright and LN-NK cells display longer telomeres than PB-CD56dim
PB-CD56bright, PB-CD56dim and LN-NK cells were sorted with high purity from different donors (A, 
one representative PB-NK cell sorting is depicted) by us and evaluated for their telomere length in 
cooperation with the Department of Human Pathology, University of Messina, Italy. (B) Relative te-
lomere lengths (RTL) of PB-CD56bright and PB-CD56dim NK cells are shown. RTL was calculated as 
described in Materials and Methods. Mean RTL value ± SD of CD56bright NK cells (white bar) com-
pared to the CD56dim NK cells (grey bar) of seven individual donors are shown (** p  0.01, as calcu-
lated by paired Student’s t test). (C) RTL values of PB-CD56bright (white bar) and CD56dim NK cells 
(grey bar) derived from two donors, included in (B), were compared to RTL values of autologous 
CD45RA+ RO- CD27+ naïve (black striped bar) and CD45RO+ RA- memory (grey striped bar) CD4+ T 
cells. Mean RTL value ± SD are depicted. (D) Telomere length of LN-NK cells (white bars) and PB-
CD56dim NK cells (grey bars) were compared. Mean RTL value ± SD of 4 donors (* p  0.05 by paired 
Student’s t test). (E) Telomere length was analysed in total LN-derived NK cells sorted ex vivo (RTL 
set as 100%, white bars), in the same cells after 3 week culture with 100 IU/ml of IL-2 (black bar) and 
in autologous PB-CD56dim NK cells (grey bars). Mean RTL value ± SEM.  
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4.1.3 CD56bright NK cells acquire signature of CD56dim NK cells upon cytokine stimula-
tion
Although analysis of CD56bright versus CD56dim versus IL-2 activated CD56dim NK cell 
gene signature has been performed (26), no clear data exist concerning modulation of PB-
CD56bright NK cell phenotype after activation and in particular during proliferation.  
Since stimulation with cytokines results in activation and subsequent proliferation prefer-
entially of CD56bright NK cells, it was tested, whether upon cytokine stimulation CD56bright can 
acquire the signature of CD56dim NK cells. To this aim, CFSE-labelled PB-CD56bright and 
CD56dim NK cells were cultured with IL-2, IL-12 or IL-15 for 5 days to induce proliferation, 
and modulation of markers which are differentially expressed between the two subsets, i.e. 
IL7R, c-kit, CXCR3, CCR7, CD62L (mainly expressed on CD56bright NK cells), granzymeA 
and granzymeB (almost confined to CD56dim NK cells) was investigated. After 5 days of cy-
tokine stimulation, changes in expression of each molecule was assessed comparing its mean 
fluorescence intensity (MFI) among cells which have undergone extensive proliferation, as 
determined by the loss of CFSE intensity, to the MFI among resting cells cultured in medium 
(Figure 3, A and B, first column) for the same period of time. Notably, expression of each 
molecule analysed ex vivo did not significantly change after 5 days of culture in medium 
alone, i.e. without cytokines (data not shown).  
As shown in Figure 3 A, CD56bright NK cells down-regulated surface expression of IL7R, 
c-kit, CXCR3 and CCR7 after IL-2, IL-12 (and IL-15, data not shown) culture in stimulated 
cells compared to resting ones kept in medium. Remarkably, down-regulation of cell surface 
expression of these molecules was not necessarily related to proliferation, as MFI decreased 
already in non-dividing cells cultured in the presence of cytokines when compared to the ones 
kept in medium only. CD62L expression on CD56bright NK cells was strongly down regulated 
after IL-2 (and IL-15, data not shown) stimulation, while even up regulated by IL-12 inde-
pendently of proliferation. Although entering the cell cycle, CD56dim NK cells did not acquire 
any of these molecules under the same culture conditions, with the exception of CD62L, 
which was partly induced on CD56dim NK cells after IL-12 stimulation (Figure 3 B). Intracel-
lular staining of cytokine stimulated CD56bright NK cells revealed that they acquired cytolytic 
molecules such as granzymeA and granzymeB upon all stimulating conditions (Figure 3 A, 
and data not shown for IL-15), while the same molecules remained rather stable or were even 
up-regulated in CD56dim NK cells (Figure 3 B).  
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Figure 3: PB-CD56bright NK cells acquire signature of CD56dim NK cells upon cytokine 
activation
Sorted CD56bright (A) or CD56dim NK cells (B) were CFSE-labelled and cultured in the presence of 
medium, IL-2 or IL-12. Because a fraction of CD56dim NK cells can express CD62L, for this experi-
ment (fifth row), CD56dim NK cells were negatively sorted for CD62L. At day 5, modulation of the 
indicated surface or intracellular molecule was evaluated comparing mean fluorescence intensity 
(MFI) among resting (right gate) and proliferating (left gate) cells, as depicted in each dot plot.  
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Concerning the expression of CD56, no down-regulation was expected on CD56bright NK 
cells, since it is known that high levels of CD56 are induced and maintained in all NK cells 
during activation. Nevertheless, LN-NK cells that have been stimulated with IL-2 down regu-
lated their level of CD56 expression following IL-2 withdrawal, while KIR expression was 
maintained (data not shown).  
 
4.1.4 PB-CD56bright NK cells can acquire KIR and CD16 expression upon cytokine acti-
vation
Some reports have shown, that CD16, which is expressed by the majority of PB-CD56dim 
NK cells, can be down regulated (58, 59), suggesting that CD56bright CD16- NK cells might 
represent activated CD56dim NK cells. In contrast, down-regulation of KIR expression from 
PB-CD56dim KIR+ NK cells has never been reported so far.  
In order to investigate modulation of CD16 expression by cytokine stimulation, CD56bright 
CD16- and CD56dim CD16+ NK cells were sorted, CFSE labelled and cultured as described in 
Figure 3. Analysis of CD16 surface expression at day 5 of culture showed that significant 
CD16 expression occurs on the majority of CD56bright CD16- NK cells after IL-2 (and IL-15, 
data not shown) stimulation while IL-12 was less efficient (Figure 4, upper panel). As previ-
ously reported (58), partial loss of CD16 expression was observed on CD56dim CD16+ NK 
cells in the presence of IL-12, as well as when cells were left for 5 days in medium alone, al-
though they have been previously sorted with very high purity for CD16 expression (Figure 4, 
lower panel).  
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Figure 4: PB-CD56bright NK cells up-regulate CD16 expression upon cytokine activa-
tion.
CD56bright CD16- and CD56dim CD16+ NK cells were sorted, CFSE-labelled and cultured in the pres-
ence or in the absence of IL-2 or IL-12. At day 5, modulation of surface CD16 expression was evalu-
ated after staining with anti-CD16 antibody. Percentages of CD16+ cells are indicated in each dot plot. 
One representative experiment out of five is shown. 
To evaluate alterations of KIR expression in the distinct PB-NK cell subsets, NK cells were 
sorted with high purity after staining with a combination of all available anti-KIR (anti-
KIR2DL2/S2/L3, KIR2DL1/S1, -KIR3DL1/S1/L2) antibodies. CFSE-labelled CD56bright KIR-
, CD56dim KIR+ and CD56dim KIR- NK cells were cultured in the presence of IL-2, IL-12 or 
IL-15 and analysed for KIR surface expression at day 5. As shown in Figure 5 A, both 
CD56bright KIR- (top row) and CD56dim KIR- NK cells (middle row) exhibited de-novo expres-
sion of KIR on a significant proportion of cells in response to IL-2 (and IL-15, data not 
shown) and in lower percentage in response to IL-12. In contrast, none of these stimuli was 
able to down-regulate KIR expression on sorted CD56dim KIR+ NK cells, which was even up-
regulated after IL-2 stimulation (Figure 5 A, bottom row). As previously shown, CD56bright 
NK cells displayed a higher proliferative response both to IL-2, IL-15 and IL-12 compared to 
total CD56dim NK cells.  
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Nonetheless, the comparison of the proliferative ability at day 5 of CD56bright in response to 
50ng/ml of IL-2 (percentage of mean proliferation ± SEM = 92.5% ± 1.6) with the one of 
CD56dim KIR- (67.7% ± 9.5) or KIR+ NK cells (26.4% ± 5.8) showed that CD56bright prolifer-
ate slightly more than CD56dim KIR- NK cells (p  0.05), while CD56dim KIR+ proliferate sig-
nificantly less compared not only to CD56bright (p  0.002) but also to KIR- NK cells (p  
0.015) (Figure 5 A), suggesting that expression of KIR might correlate with a terminally dif-
ferentiated phenotype. Outstandingly, the lower proliferative capacity of KIR+ NK cells ex-
cludes the possibility that rare contaminating KIR+ NK cells could overgrow CD56bright and 
CD56dim KIR- NK cells and be responsible for detection of KIR expression among KIR- NK 
cells. 
In order to investigate more in detail which KIR could be induced on the surface of 
CD56bright or CD56dim KIR- NK cells, NK cell subsets were sorted as previously described and 
analysed for single KIR expression after 5 days of culture in IL-2. As shown in Figure 5 B, 
each KIR expressed ex vivo on CD56dim KIR+ NK cells (left column) could be induced on the 
surface of CD56bright KIR- or CD56dim KIR- NK cells (right columns) by cytokine stimulation. 
Next, in donors in which staining of single KIR was performed, mRNA expression of KIR2D 
and KIR3D ORF (see materials and methods) and of their activating or inhibitory counterparts 
was analysed either directly after sorting or at day 5 of IL-2 culture. RT-PCR was performed 
in cooperation with Michela Falco from the Institute Giannina Gaslini, Genoa, Italy. As 
shown in Figure 5 C, IL-2 stimulation induced mRNA expression of both inhibitory and acti-
vating KIR both in CD56bright and CD56dim KIR- NK cells. The signal detectable in CD56dim 
KIR- NK cells for all KIR ORF mRNA at day 0 after sorting seems to be mainly related to 
activating rather than inhibitory KIR. Indeed, this could be due to the use of primers recogniz-
ing not only KIR2DL2/S2/L3, KIR2DL1/S1, -KIR3DL1/S1/L2 (stained for FACS sorting) but 
also KIR2DS3/S4/S5 for which NK cells could not be negatively sorted due to the lack of 
specific antibodies. 
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Figure 5: PB-CD56bright and CD56dim KIR- NK cells express KIR upon cytokine activa-
tion.
Sorted NK cell subsets were CFSE-labelled and cultured in the presence or in the absence of IL-2 or 
IL-12 for 5 days. At day 5, modulation of KIR expression was evaluated. (A) CD56bright, CD56dim KIR- 
and CD56dim KIR+ NK cells were stained with a combination of antibodies specific for 2D KIRs and 
3D KIRs. One representative experiment out of six is shown. (B) Ex vivo expression of single KIR 
after staining with antibodies directed against KIR2DL2/L3/S2, KIR2DL1/S1 or KIR3DL1 (left col-
umn) on total NK cells was evaluated. CD56bright, CD56dim 2+3D KIR- and CD56dim 2+3D KIR+ NK 
cells were sorted. Purity check of the sorted subsets from one representative experiment is shown 
(middle column). After IL-2 culture, induction of each single KIR on the sorted NK cell subsets (right 
columns) was measured. One representative experiment out of three is shown. (C) Total RNA was 
isolated from sorted CD56bright, CD56dim 2+3D KIR- and CD56dim 2+3D KIR+ NK cell subsets derived 
from the same donor shown in (B). PCR products obtained using sets of primers specific for KIR3D 
(first lane, upper band) and KIR2D (first lane, lower band) ORF transcripts, and their inhibitory (sec-
ond lane) or activating (third lane) counterparts are shown. RT-PCR of a beta actin segment (fourth 
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lane) was used as positive transcription control. Analysis was performed directly after sorting or after 5 
day culture in IL-2. One representative experiment out of two is shown. 
 
4.1.5 Secondary lymphoid organs can be site of NK cell maturation 
It has recently been suggested that SLO might be sites of NK cell differentiation (50, 52). 
If this was indeed the case, NK cells leaving LN should be different from NK cells resident in 
LN. To this aim, in cooperation with Guido Ferlazzo, NK cells isolated from the efferent 
lymph system (i.e. thoracic duct) and from autologous LN have been analysed in parallel. 
Consistent with previous reports (49, 50), NK cells located in non reactive LN displayed low 
or no KIR and CD16 expression (Figure 6 A). Alternatively, a significant fraction of NK cells 
collected from the efferent lymph of the thoracic duct expressed KIR and CD16, although the 
latter to a lower extent than their blood counterpart (Figure 6 A). These data cannot rule out 
the possibility that a small percentage of CD56dim NK cells expressing KIR and CD16 enters 
the LN, expands in situ and then leaves LN via efferent lymph. Nonetheless, considering the 
lower proliferative ability and the chemokine receptor expression of CD56dim CD16+ KIR+ NK 
cells, the hypothesis that NK cells can acquire de novo expression of relevant functional 
molecules in LN and then circulate to PB through the efferent lymph can be favoured.  
The observation that NK cells emigrating from, but not resident in LN, express KIR and 
CD16 (Figure 6 A), raised the question whether KIR and CD16 acquisition occurs only in 
reactive or as well in non-reactive LNs. Therefore, NK cells isolated from 28 LN of 14 indi-
vidual donors were analysed. As shown in Figure 6, a significant percentage of NK cells ex-
pressing KIR was detectable only in reactive LN characterized by paracortical/follicular hy-
perplasia (mean percentage ± SEM: 7.3 ± 0.3, Figure 6 C), which is branded by the presence 
of secondary follicules and lymphocyte proliferation (Figure 6 B, iii-vi). NK cells isolated 
from non-reactive LN (Figure 6 B, i-ii) or LN with sinus hyperplasia (characterized by an 
increased number of macrophages) showed low or no expression of KIR (mean percentage ± 
SEM: 1.75 ± 0.2, Figure 6 C). In addition, CD16 expression correlated with LN-
paracortical/follicular hyperplasia (data not shown) (77). Because of the strong association of 
KIR and CD16 expression with LN-paracortical/follicular hyperplasia (p  0.002), it could be 
hypothesized that KIR expression in LN NK cells might represent a de novo induction of 
these molecules occurring on LN resident CD56bright NK cells in the course of an inflamma-
tory immune response, were different cytokines (e. g. IL-15, IL-12 and IL-2) are present. 
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Figure 6: NK cells from efferent lymph and from LN with paracortical/follicular hy-
perplasia express KIR and CD16. 
This experiment was performed by Guido Ferlazzo, University of Messina, Italy. 
(A) Mononuclear cells were isolated from efferent lymph (i.e. thoracic duct), LN and PB of the same 
donor. CD16 and KIR expression was analysed gating on NK cells. One representative experiment out 
of two is shown. (B) Sections of paraffin-embedded tissue of 28 LN were stained with Hematoxylin-
Eosin. 3 LN that are representative of distinct inflammatory conditions as detected by histological 
analysis out of the 28 analysed are shown. (i): non reactive LN, magnification 5X. (ii): detail of a folli-
cle shown in (i), magnification 40X. (iii): LN paracortical hyperplasia: manifest enlargement of the 
paracortical area between capsula and follicles, magnification 5X. (iv): detail of the paracortical area 
shown in (iii), magnification 40X. (v): LN follicular hyperplasia, magnification 5X. (vi): detail of the 
follicular hyperplasia showing the presence of several plasma cells. (C) Percentage of KIR expressing 
NK cells isolated from LN exhibiting paracortical or follicular hyperplasia or combination of the 2 
(triangles) or from LN displaying no reactivity or sinus hyperplasia (circles), according to the histo-
logical analysis. The median value for each group is depicted (p  0.0018 by Mann-Whitney test). In 
order to correlate LN inflammatory status and NK cell KIR or CD16 expression, LN were incised im-
mediately after removal and split into two sagittal parts, one of which was paraffin embedded in order 
to perform histology, while the other was processed for single cell isolation and analysed by flow cy-
tometry. 
Results           45  
 
Altogether, the results of this first part suggest that CD56bright and CD56dim NK cells corre-
spond to sequential steps of differentiation, i.e. CD56bright NK cell are precursors and can give 
rise to CD56dim cells and support the hypothesis that secondary lymphoid organs can be sites 
of NK cell final maturation and self-tolerance acquisition during an immune reaction. 
 
4.2 Education of hyporesponsive NK cells by cytokines 
 
In the first part of this study it was shown that under the influence of cytokines CD56bright 
can differentiate in vitro and in vivo into cells similar to CD56dim ones. During this process 
they acquire on the one hand cytotoxic effector molecules such as granzymes (Figure 3) and 
perforin (data not shown) and on the other hand inhibitory receptors, i.e. KIRs (Figure 5 and 
6), a prerequisite for the discrimination of self from non self and thereby for tolerance towards 
self.  
NK cell tolerance to self is mediated via engagement of inhibitory receptors by cognate 
MHC molecules. In humans, inhibitory receptors include KIRs, exclusively expressed by 
CD56dim, and the CD94/NKG2A heterodimer, present on all CD56bright and on a subset of 
CD56dim NK cells. It has been shown that expression of at least one self-specific inhibitory 
receptor is critical for NK cell education to achieve functional competence. Thus, NK cells 
expressing self-MHC specific inhibitory receptors are responsive to activating stimuli while 
those lacking such receptors (KIR-NKG2A-) are hyporesponsive (37-40). Nevertheless, the 
mechanisms underlying NK cell education are still poorly understood. In the second part of 
this thesis it was investigated whether cytokine induced expression of self specific inhibitory 
receptors results in education of hyporesponsive NK cells to become competent and self toler-
ant. 
 
4.2.1 Cytokines induce stable expression of inhibitory receptors on hyporesponsive 
CD56dim KIR- NKG2A- NK cells
CD56dim NK cells that do not express any inhibitory receptor specific for MHC-class I, 
have been shown to be hyporesponsive after stimulation with MHC class I negative targets 
(39, 40, 78). Nonetheless, it is still debated whether this NK cell subset maintains its pheno-
type during inflammation, when receiving different types of signals, including cytokines.  
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Accordingly, it was investigated whether cytokines are able and sufficient to induce ex-
pression of inhibitory receptors not only in CD56bright and CD56dim KIR- NK cells, as shown 
in Figure 5, but also in CD56dim KIR- NKG2A- ones.  
Stimulation of sorted CD56dim KIR- NKG2A- NK cells with IL-2, IL-15 (Figure 7 A), IL-12 
or IL-12 plus IL-18 (data not shown) resulted in KIR induction on a fraction of NK cells earli-
est at day 2. De novo expression of KIRs was maintained until day 16 and progressively de-
creased until day 26. Moreover, induction of KIR expression was not restricted to KIR- 
NKG2A- cells but could be also observed in cells, which were already positive for one or 
more KIRs (Figure 7 B). In contrast to KIR expression, NKG2A expression was induced al-
ready at day 1 on the majority of KIR- NKG2A- NK cells and remained stable for the duration 
of the culture (Figure 7 A) with only small changes depending upon the activation status of 
the cells. These data show that cytokines alone are sufficient to induce expression of KIRs and 
NKG2A on hyporesponsive KIR- NKG2A- NK cells.  
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Figure 7: Cytokines induce KIR and NKG2A expression on hyporesponsive KIR-
NKG2A- NK cells 
(A) Sorted CD56dim KIR- NKG2A- NK cells were cultivated in the presence of IL-2 or IL-15 and ana-
lysed for KIR and NKG2A expression after staining with a combination of antibodies specific for 2D 
KIRs and 3D KIRs and anti-NKG2A at different time points. Percentage of KIR induction is shown. 
One representative experiment out of three is depicted. (B) Sorted CD56dim KIR2DL1+ KIR2DL2/3- 
KIR3DL1- NK cells were cultivated in the presence of IL-2 and analysed for KIR expression at day 9 
of culture. Percentage of KIR induction in one representative experiment out of three is shown. 
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As shown in Figure 7, KIR expression slowly disappeared over time. This finding implies 
two possible explanations: either KIR- NK cells overgrow the KIR+ ones, as it has been previ-
ously demonstrated that KIR- NK cells have a higher proliferative capacity than KIR+ cells 
(Figure 5) (78), or KIRs are down-regulated. In order to rule out the last possibility, KIR- 
NKG2A- NK cells which after IL-2 culture expressed a single KIR (in this case KIR3DL1) 
were again sorted and cultivated in IL-2 for additional 12 days (Figure 8). In parallel, ex vivo 
sorted KIR3DL1+ NK cells were also cultivated in IL-2 for the same period. As shown in Fig-
ure 8, KIR3DL1 expression induced by a first round of IL-2 stimulation remained stable on 
the majority of cells during the second round of IL-2 culture (Figure 8), once KIR3DL1+ cells 
were again purified. However, within KIR3DL1+ cells generated in vitro, a slightly higher 
percentage of cells appeared to lose KIR3DL1 expression as compared to the ex vivo 
KIR3DL1+ sorted ones, indicating that KIRs acquired in vivo are probably more stable than 
those acquired in vitro. Remarkably, NK cells which did not acquire any KIR expression in 
the first 12 days of IL-2 or IL-15 stimulation failed to do so in the following 12 days of cul-
ture (Figure 8), while NKG2A could be still significantly induced (data not shown).  
 
 
 
 
 
Results           49  
 
 
Figure 8: Cytokines induce stable KIR3DL1 expression on a subset of KIR- NKG2A-
NK cells
CD56dim KIR3DL1- 2D KIR- NKG2A- NK cells were sorted and cultivated for 12 days in the presence 
of IL-2 to induce expression of KIR3DL1. At day 12, NK cells were stained for KIR3DL1 and a com-
bination of antibodies specific for 2D KIRs. KIR3DL1+ 2D KIR- and KIR3DL1- 2D KIR- NKG2A- 
cells were re-sorted (2nd Sort) and cultivated for additional 12 days with IL-2. As control, ex vivo iso-
lated KIR3DL1+ NK cells were also cultivated and re-sorted. One representative experiment out of 
four is depicted. 
 
Overall, these data demonstrate that cytokines are sufficient to induce a rather stable ex-
pression of KIRs on a subpopulation of KIR- NKG2A- NK cells and of NKG2A on the major-
ity of cells. 
 
4.2.2 Acquisition of self specific KIRs after cytokine stimulation confers competence to 
CD56dimKIR-NKG2A- hyporesponsive NK cells 
Since ex vivo expression of self-specific inhibitory receptors correlates to NK cell func-
tional competence (39, 40), it was analysed whether acquisition of KIR expression after cyto-
kine stimulation confers competence to CD56dim KIR- NKG2A- hyporesponsive NK cells and 
if engagement of self-MHC is required.  
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To answer these questions, KIR3DL1 expression was induced in CD56dim KIR- NKG2A- 
NK cells from HLA-Bw4 or HLA-Bw6 individuals, which do or do not express the cognate 
MHC ligand for KIR3DL1, respectively. After 12 days of IL-2 culture, 13.5 ± 4% of KIR- 
NKG2A- cells expressed at least one KIR. The percentage of KIR3DL1+ NK cells was 3.3 ± 
1.7% among HLA-Bw4 and 1.9 ± 1% in HLA-Bw6 individuals (p 0.15, as calculated by 
Wilcoxon test), thus showing that induction of a certain KIR does not require the presence of 
the cognate MHC ligand. Cells, which expressed exclusively KIR3DL1, were compared to 
cells remaining KIR- NKG2A- for their cytotoxic competence by measuring surface expression 
of CD107a, a marker for degranulation, after stimulation with the MHC class I negative tu-
mour cell line K562. As shown in Figure 9 A, NK cells that acquired KIR3DL1 in HLA-Bw4 
individuals displayed significantly higher CD107a expression than NK cells, which remained 
KIR- NKG2A-, suggesting that acquisition of KIRs correlates with functional competence. In 
order to confirm that only acquisition of self specific KIRs correlated with induction of func-
tional competence in hyporesponsive NK cells, the same experiment was performed analyzing 
NK cells derived from HLA-Bw6 individuals, which do not express the cognate ligand for 
KIR3DL1. In contrast to what has been observed in HLA-Bw4 individuals, single KIR3DL1+ 
NK cells generated from HLA-Bw6 individuals after IL-2 culture remained as hyporesponsive 
as KIR- NKG2A- NK cells (Figure 9 A). These data demonstrate that cytokine stimulation 
results in education of hyporesponsive KIR- NKG2A- NK cells by inducing self-MHC specific 
KIRs, as it occurs only in HLA-Bw4 but not in HLA-Bw6 individuals. Moreover, this finding 
supports the concept that KIR engagement with the corresponding self-MHC ligand is re-
quired for this process.  
As stimulation with IL-2 induces expression not only of inhibitory receptors but also of 
several molecules involved in NK cell activation and cytotoxicity, expression levels of activat-
ing receptors namely NKp30, NKp46, NKG2D, of CD3 chain, and of lytic molecules, 
namely perforin and granzymes in KIR3DL1+ and KIR- NKG2A- NK cells from HLA-Bw4 
individuals generated after IL-2 culture were compared. As shown in Figure 9 B, both NK cell 
subsets displayed comparable expression levels of each molecule analysed, suggesting that 
none of them is involved in induction of NK cell competence by cytokines. 
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As demonstrated in Figure 9 A, expression of self-MHC specific KIRs induced by cytokine 
stimulation confers cytotoxic competence to previously hyporesponsive NK cells. Since hy-
poresponsiveness is the mechanism that enables KIR- NKG2A- cells to keep tolerance towards 
self, it had to be investigated whether cytokine stimulation would lead to the development of 
potentially autoreactive NK cells. To this end, the cytotoxic potential of KIR3DL1+ NK cells 
generated from HLA-Bw4 individuals after cytokine stimulation against 721.221 transfectants 
expressing or not expressing the MHC class I ligand for KIR3DL1, i.e. HLA-Bw4 was evalu-
ated. As already observed for stimulation using K562 as target cells (Figure 9 A), cytokine 
generated KIR3DL1+ NK cells displayed higher CD107a expression after stimulation with 
721.221 targets than cells remaining KIR- NKG2A- (data not shown). Notably, lysis of 
721.221 could be significantly inhibited by the expression of HLA-Bw4, but not of HLA-
Bw6, demonstrating that cytokine induced KIRs are functional and render KIR+ NK cells tol-
erant versus cells that express the cognate self-MHC ligand (Figure 9 C).  
These data show that induction of competence correlates with acquisition of functional in-
hibitory receptors specific for self-MHC and therefore should not result in autoreactivity, 
since hyporesponsiveness is replaced by MHC-dependent inhibition. 
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Figure 9: Acquisition of self-MHC specific KIRs confers cytotoxic competence to hy-
poresponsive NK cells. 
(A) IL-2 cultured CD56dim KIR3DL1- 2D KIR- NKG2A- NK cells were stimulated with K562, stained 
for KIR3DL1 and a combination of antibodies specific for 2D KIRs and CD107a expression was 
measured after gating on KIR3DL1+ 2D KIR- NKG2A- or KIR3DL1- 2D KIR- NKG2A- NK cells. 
Mean values ± SEM of six HLA-Bw4 (left) and six HLA-Bw6 individuals (right) are shown. (B) Ex-
pression of the indicated molecules and their isotype control was analysed in IL-2 generated 
KIR3DL1+ 2D KIR- NKG2A- (solid line and gray-filled histogram) or KIR3DL1- 2D KIR- NKG2A- 
NK cells (dashed line and light gray-filled histogram). (C) CD107a expression after stimulation with 
the 721.221 parent cell line or 721.221 transfectants expressing HLA-B51 (HLA-Bw4) or HLA-B7 
(HLA-Bw6) was assessed gating on KIR3DL1+ 2D KIR- NK cells generated after IL-2 culture. Values 
derived from one representative experiment out of three are shown. All p values were calculated by 
Wilcoxon test. * indicates p<0.05.  
 
Altogether, the data shown in the second part of my thesis clearly demonstrate that compe-
tent NK cells can be generated by cytokine stimulation, suggesting that NK cell education 
might not only be an early event which takes place during NK cell development but might 
also occur in the periphery during an immune response.  
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4.3 CD62L expression identifies a subset of polyfunctional CD56dim NK cells 
 
In the first two parts of this thesis it was shown that under the influence of cytokines 
CD56bright can differentiate into CD56dim NK cells and that cytokine induced acquisition of 
inhibitory receptors results in the generation of competent and self-tolerant NK cells. In the 
third part, the heterogeneity of the CD56dim NK cell compartment with regard to expression of 
other markers than inhibitory receptors and with respect to functional properties associated to 
expression of these molecules has been elucidated.  
As described already before, human NK cells comprise two main subsets that differ in 
function, phenotype and tissue localization, the CD56bright and the CD56dim NK cells (3.1). 
However, CD56dim NK cells represent as well a heterogeneous population concerning the ex-
pression of several markers, such as inhibitory receptors (3.1 and 3.2), CD62L or CD27. The 
aim of this part was to analyse how the expression of CD62L and of other markers correlates 
to different NK cell functions such as proliferation, cytokine production and cytotoxicity in 
order to identify intermediate stages of NK cell maturation and to better define the differentia-
tion history of human NK cells. 
 
4.3.1 CD56bright and CD56dim CD62L+ NK cells display similar proliferative capacity in 
vivo and in vitro 
CD56bright NK cells have been shown to exhibit a much higher capacity to proliferate after 
in vitro stimulation with cytokines or dendritic cells (DC) than CD56dim NK cells (Figure 3-5) 
(19, 30, 70). Since CD56dim cells are not a homogenous population concerning the expression 
of several surface markers including CD62L (Figure 1), we first compared the proliferative 
ability of CD56bright, CD56dim CD62L+ and CD56dim CD62L- subsets after stimulation with 
cytokines or PB-derived myeloid (mDC). Activation with IL-2 (Figure 10 A and B), IL-15, 
IL-12 or DC (Figure 10 A) resulted in higher proliferation of CD56bright and CD56dim CD62L+ 
cells as compared to CD56dim CD62L- ones. CD56bright NK cells proliferated slightly more 
than CD56dim CD62L+ ones only at high concentrations of IL-2 (Figure 10 B), while the dif-
ference in proliferation efficiency between the two subsets became more striking at very low 
concentrations of IL-2 (Figure 10 C). 
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Figure 10: CD56bright and CD56dim CD62L+ NK cells display similar proliferative ca-
pacity in vitro 
Analysis of in vitro proliferation of NK cell subsets was measured by CFSE labelling after different 
stimuli. (A) One representative experiment out of ten is shown. Stimulated (open histograms) and un-
stimulated (gray-filled histograms) cells as well as the percentage of proliferating cells are depicted for 
each condition. (B) Mean percentage ± SEM of proliferating cells after high dose of IL-2 stimulation 
of ten independent experiments is shown. **: p< 0.01 was calculated by Wilcoxon test. (C) In vitro 
proliferation of NK cell subsets was measured after decreasing concentrations of IL-2 (100ng/ml to 
1ng/ml); one representative experiment out of four is shown. 
 
To determine whether the ability to proliferate in vitro actually mirrors what happens in
vivo, PBMCs derived from healthy donors were stained directly ex vivo for Ki67, which is 
expressed in G1, G2, S and M phases, but not in G0 phase of the cell cycle (79, 80), and gated 
on T cells, total NK cells or the indicated NK cell subsets. In Figure 11 A, left panel, a repre-
sentative Ki67 staining before vaccination in CD56bright, CD56dim CD62L+ and CD62L- NK 
cells is shown, while the right panel summarizes ex vivo expression of Ki67 in NK cell sub-
sets of 22 donors.  
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These data clearly demonstrate that a consistent number of NK cells was undergoing ho-
meostatic proliferation in vivo or has been recently activated due to an ongoing immune re-
sponse and that within CD56bright and CD56dim CD62L+ NK cells more in vivo proliferating 
cells can be detected compared to CD62L- ones. To investigate the proliferative response of 
NK cells in the course of a defined immune response, healthy donors were vaccinated with the 
live yellow fever virus (YFV)-17D. Immunization with YFV-17D vaccine results in a self-
limiting acute viral infection with viral replication and therefore represents an ideal setting to 
assess NK cell proliferation during an immune response. Comparative analysis of Ki67 ex-
pression directly before and after YFV-17D vaccination revealed that the frequency of prolif-
erating NK cells was significantly increased at day 7 compared to day 0 (Figure 11B, left) and 
returned to basal levels by day 28 (Figure 11B, middle). This data clearly indicates that a con-
sistent proportion of NK cells were proliferating in vivo in response to viral infection. Impor-
tantly, cells which were proliferating at day 7 after YFV-17D vaccination were again com-
prised mostly within CD56bright and CD56dim CD62L+ NK cell subsets (Figure 11B, right), 
demonstrating that the high proliferative ability displayed in vitro by these two subsets actu-
ally reflects their in vivo behaviour during a viral infection.  
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Figure 11: CD56bright and CD56dim CD62L+ NK cells display similar proliferative ca-
pacity in vivo after Yellow Fever Virus vaccination
Analysis of in vivo proliferation of NK cell subsets was measured after ex vivo Ki67 staining of 
PBMC derived from healthy donors. (A) One representative donor (left panel) and mean percentage of 
Ki67+ cells ± SEM of 22 donors analysed (right panel) is shown. (B) Ki67 expression was analysed 
directly before (day 0), or after YFV vaccination (day 7 and 28) gating on total CD3- CD56+ NK cells 
(left and middle) or on CD56bright (black circles), CD56dim CD62L+ (dark grey triangles) and CD56dim 
CD62L- (light grey squares) (right). Percentage of Ki67+ cells of 8 donors and median of all values 
(left and right graphs) or mean percentage ± SEM of Ki67+ cells of 3 donors (middle) are depicted. * 
p<0.05; ** p<0.01; *** p< 0.0001 as calculated by Wilcoxon test  
 
Overall, these data show that CD56bright and CD56dim CD62L+ NK cells have high prolif-
erative ability both in vitro after stimulation with cytokines or dendritic cells and in vivo dur-
ing an ongoing viral infection. 
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4.3.2 Differences in phosphorylation levels of STAT5 partially account for the higher re-
sponsiveness of CD56dim CD62L+ cells to IL-2 and IL-15 stimulation 
The ability of CD56bright NK cells to efficiently respond to cytokine stimulation has been 
associated to the expression of the high affinity IL-2 receptor alpha chain, CD25 (22), and to 
higher phosphorylation levels of transcription factors such as ERK after cytokine stimulation 
(81). Since, CD56dim CD62L+ cells show similar proliferative ability to CD56bright NK cells 
(Figure 10 and 11), it was analysed, whether differences in cytokine receptor expression could 
account for the superior proliferative ability of CD56dim CD62L+ as compared to CD62L- NK 
cells. Yet, with the exception of the IL-2Rchain, which was exclusively expressed on 
CD56bright cells as previously shown (22), CD56bright and both CD56dim subsets displayed simi-
lar amounts of the receptor subunits, analysed (Figure 12 A). Moreover, CD25 could still be 
up regulated between day 1 and 5 on CD56dim CD62L+ as well as on CD62L- NK cells (data 
not shown). Therefore, while expression of CD25 on resting CD56bright cells might at least 
partially explain their higher proliferative ability, differences in cytokine receptor expression 
could not account for the distinct proliferative behaviour of CD56dim CD62L+ or CD62L- 
cells. For that reason, phosphorylation of the STAT5, a transcription factor that becomes 
phosphorylated after activation of the common chain receptor, was analysed. In line with 
that what has been shown for ERK (81), IL-2 (Figure 12 B) or IL-15 (Figure 12 B and C) 
stimulation resulted in high STAT5 phosphorylation in CD56bright cells. Notably, despite no 
major differences in cytokine receptor expression between the two CD56dim subsets, CD62L+ 
displayed intermediate levels of p-STAT5 between CD56bright and CD62L- cells both after IL-2 
(Figure 12 B) and IL-15 stimulation (Figure 12 B and C). These data imply that differences in 
phosphorylation intensity of STAT5 might at least partially account for the better responsive-
ness of CD56dim CD62L+ NK cells to IL-2 and IL-15 stimulation.  
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Figure 12: Differences in Phosphorylation levels of STAT5 account for the higher re-
sponsiveness to IL-2 and IL-15 stimulation 
(A) Ex vivo staining of CD25 (IL-2R), CD122 (IL-15/IL-2R chain) and CD132 (common  chain) 
(open histogram) and corresponding isotype control staining (gray-filled histogram) on CD56bright, 
CD56dim CD62L+ and CD56dim CD62L- NK cells, MFI of specific staining minus MFI of isotype stain-
ing of one representative donor out of three is depicted. (B and C) Phosphorylation levels of STAT5 
after stimulation of sorted CD56bright, CD56dim CD62L+ or CD62L- NK cells for 15 minutes with IL-15 
(B, C) or IL-2 (B), one representative experiment out of six for IL-15 and out of 4 for IL-2 stimulation 
is shown. MFI of stimulated (black histogram) minus MFI of unstimulated control (filled grey histo-
gramm) is depicted. (C) Mean p-STAT5 MFI ± SEM after stimulation in the presence of IL-15 of six 
independent experiment is shown, * p<0.05 as calculated by Wilcoxon test. 
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4.3.3 CD56dim CD62L+ expression identifies NK cells with high ability to produce IFN-
after stimulation with cytokines or dendritic cells 
In addition to their high proliferative capacity, CD56bright NK cells are characterized by the 
higher ability to produce IFN- as compared to total CD56dim NK cells after stimulation with 
cytokines or dendritic cells (19, 30, 70). Since with respect to proliferation, CD56dim CD62L+ 
behaves more similar to CD56bright than to the rest of the CD56dim (Figure 10- 12), IFN- pro-
duction in both CD56dim subsets compared to CD56bright cells was analysed. As shown in Fig-
ure 13 A and B (left), CD56bright and CD56dim CD62L+ NK cells contained similar percentages 
of IFN- secreting cells after stimulation with IL-12 and IL-18 or after co culture with PB-
derived myeloid dendritic cells (Figure 13 A). Conversely, only a minority of CD62L- NK 
cells was able to produce IFN- under the same conditions. In addition, the amount of IFN- 
expression per cell as measured by mean fluorescence intensity (MFI) was significantly 
higher in CD56bright and in CD56dim CD62L+ cells compared to CD62L- NK cells (Figure 13 
B, right), thus showing that the first two subsets are competent IFN- producers. These find-
ings indicate that also CD56dim CD62L+ NK cells might contribute to an immune response 
with high amounts of IFN- after DC or cytokine stimulation and therefore could play an im-
mune-regulatory role similar to what has been shown for CD56bright cells.  
 
Figure 13: IFN-production by NK cell subsets after cytokine stimulation 
IFN-production of CD56bright, CD56dim CD62L+ and CD62L- NK cells after stimulation with IL12+18 
or with PB-derived myeloid DC activated with LPS and R848, (A) one representative experiment out 
of nine is shown. Stimulated (open histograms) and unstimulated (gray-filled histograms) as well as 
percentage of IFN- producing cells are depicted for each condition. (B) Mean percentage (left) and 
Mean MFI (right) of IFN- expressing cells ± SEM of nine independent experiments is shown, * 
p<0.05; ** p<0.01, as calculated by paired students t-test  
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4.3.4 Analysis of the impact of CD62L expression versus KIR, NKG2A or CD27 on pro-
liferation and IFN-production
CD62L expression clearly correlates with proliferation and IFN- production after cytokine 
or DC stimulation. However, apart from CD62L also KIR, NKG2A and CD27 have been 
shown to be differentially expressed within the CD56dim NK cell subset (65, 66) and have 
been associated to distinct maturation status and different functional properties of NK cells in 
humans and mice (37-39, 65, 66, 82). Yet, it has been previously demonstrated that KIR+ NK 
cells proliferate less than KIR- NK cells (Figure5) and that KIR- NKG2A- NK cells proliferate 
less than KIR- NKG2A+ ones (78). Moreover, it was shown that NK cells expressing self-
MHC specific KIR or NKG2A produce more IFN- than NK cells lacking such receptors even 
after cytokine stimulation (39, 78). These results imply that expression of KIR or NKG2A can 
influence NK cell proliferative ability as well as their capacity to produce IFN-. In addition, 
it has been reported that CD27+ NK cells have a higher proliferative ability than CD27- ones 
(66). In order to interpret all these results, we first analysed coexpression of CD62L with 
NKG2A, KIR and CD27 within NK cells. As shown in Figure 14 A (left), while all CD56bright 
NK cells are CD62L+, KIR-, NKG2A+ and CD27dim, the majority of CD56dim NK cells are 
CD62L-, KIR+, NKG2A-, and CD27- with smaller proportion of cells expressing these mark-
ers. Analysis of coexpression of CD62L with NKG2A, KIR and CD27 in CD56dim NK cells 
(Figure 14 A, right, and B) revealed that although CD62L and KIR expression was not mutu-
ally exclusive, CD62L was present on a higher proportion of KIR- than KIR+ NK cells among 
CD56dim NK cells in all donors analysed. Moreover, CD62L expression positively correlated 
with NKG2A and CD27 expression (Figure 14 A and B). 
Thus, within the CD56dim NK cells, a subset of more immature cells exist that coexpresses 
CD62L and NKG2A, is negative for KIR and enriched in CD27+ cells, similar to the pheno-
type of CD56bright cells.  
 
 
Results           61  
 
 
Figure 14: Expression and Correlation of markers associated with NK cell maturation 
(A) FACS analysis of PBMCs gated on CD3- CD56+ NK cells (left) or on CD3- CD56dim NK cells 
(right), one representative donor out of eleven is shown. (B) Mean percentages ± SEM of KIR+, 
NKG2A+ or CD27+ cells within CD56dim CD62L+ and CD56dim CD62L- of 26 (KIR), 22 (NKG2A) and 
10 (CD27) different healthy donors are shown. ** p<0.01; *** p< 0.0001 as calculated by Wilcoxon 
test 
 
Because of the positive correlation between CD62L and CD27 or NKG2A and the negative 
correlation between CD62L and KIR expression, it was tested which of these markers were 
directly associated to the ability to proliferate in vivo and to efficiently produce IFN- after 
cytokine stimulation. While in vivo proliferating cells were preferentially found within 
CD56bright and CD56dim CD62L+ subsets (Figure 11 A), no significant correlation of Ki67 ex-
pression with CD27, KIR or NKG2A could be detected (Figure 15 A). These data suggest that 
CD62L and not KIR, NKG2A or CD27 expression identifies NK cells, which proliferate more 
extensively in vivo. Next, it was evaluated whether the capacity to produce IFN- after stimu-
lation with cytokines would also correlate exclusively to CD62L expression, or rather to self-
MHC class I specific inhibitory receptors such as KIR or NKG2A. Therefore, CD56dim NK 
cells derived from the PB of HLA-Bw4 individuals have been sorted into CD62L+ NKG2A+, 
CD62L+ NKG2A-, CD62L- NKG2A+ and CD62L- NKG2A- subsets, stimulated with IL-12 
plus IL-18 and afterwards stained for different KIR. IFN- expression was analysed in all 
sorted subsets after gating on “competent” cells that were single positive for the self-MHC 
class I (HLA-Bw4)-specific inhibitory receptor KIR3DL1 or on “hyporesponsive” cells nega-
tive for all KIRs.  
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Similar to proliferative ability, significantly more IFN- producing cells could be detected 
within CD56dim CD62L+ than within CD62L- cells independently of KIR or NKG2A expres-
sion (Figure 15 B), thus clearly demonstrating that IFN- production in response to cytokines 
is not influenced by the presence of self MHC class I specific inhibitory receptors or NKG2A 
but rather correlates to CD62L expression. Once the possible impact of KIR and NKG2A was 
ruled out, the impact of CD27 expression was investigated. Again, IFN- secreting cells were 
significantly more enriched within the CD56dim CD62L+ subset as compared to the CD62L- 
one, both in CD27+ as well as in CD27- cells. Remarkably, the CD56dim CD27+ CD62L+ sub-
set comprises more cells able to produce IFN- than the CD27- CD62L+ one, demonstrating 
that CD56dim CD27+ CD62L+ cells, although representing a very minor population of NK cells 
(1.8 ± 0.3%), are the most potent IFN- producers within CD56dim NK cells (Figure 15 C).  
 
 
Figure 15: Correlation of CD62L, CD27, KIR or NKG2A expression with NK cell prolif-
eration and IFN-production 
(A) Ki67 expression in PB-NK cell subsets after staining for CD62L, 2+3D KIR (indicated as KIR), 
NKG2A and CD27 and gating on CD56bright or the indicated CD56dim subsets, 7 (KIR and NKG2A) or 
8 (CD27) donors plus corresponding medians are shown. (B) CD56dim NK cells derived from HLA-
Bw4 donors were sorted for NKG2A- CD62L+ and NKG2A- CD62L- cells and stimulated with IL-
12+IL-18. After additionally staining for 2D KIR and KIR3DL1 (indicated as 3DL1), IFN expression 
was analysed within competent 2D KIR- KIR3DL1+ or hyporesponsive 2D KIR- KIR3DL1- cells. 
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Mean ± SEM of six independent experiments is shown. (C) CD56dim NK cells were sorted for CD27 
and CD62L expression and IFN- was analysed after stimulation with IL-12+18. Mean values ± SEM 
of six independent experiments are shown. * p<0.05 as calculated by Wilcoxon test.
 
4.3.5 Both, CD62L+ and CD62L- CD56dim are able to respond to activating receptor 
stimulation  
NK cells cannot only produce IFN- after cytokine stimulation but also upon engagement 
of activating receptors by stimulatory ligands expressed on target cells. It has been shown that 
simultaneous triggering of multiple activating receptors results in cytokine production and 
cytotoxicity by human resting NK cells (83). Therefore, IFN- and TNF expression after 
cross-linking of multiple activating receptors was analysed in CD56bright, CD56dim CD62L+ 
and CD62L- cells. Surprisingly, although CD56bright cells are generally considered the cyto-
kine producers, they did not express significant amounts of either IFN- or TNF after activat-
ing receptor stimulation (Figure 16 A). In contrast, both CD56dim cell subsets, CD56dim 
CD62L+ and CD62L- cells, were proficient IFN- and TNF producers after activating receptor 
stimulation (Figure 16 A). These data show for the first time that during differentiation from 
CD56bright to CD56dim, NK cells lose the ability to produce cytokines after cytokine stimula-
tion but acquire the capacity to express it after activating receptor stimulation. Comparative 
analysis of cytotoxicity towards MHC class I negative tumour target cells revealed that 
CD56dim CD62L+ and CD62L- NK cells were both able to kill, while CD56bright cells dis-
played much lower cytotoxic ability (Figure 16 B), in line with previous observations (33). 
Indeed, although CD56dim CD62L+ NK cells display many functional and phenotypic features 
in common with CD56bright, cytotoxic ability (Figure 16 B) as well as ex vivo expression of 
perforin, granzymeA and granzymeB (Figure 16 C) was comparably high in CD56dim CD62L+ 
and in CD62L- cells. Thus, these data demonstrate that CD56dim CD62L+ NK cells are not 
only able to extensively proliferate and to produce IFN- after cytokine stimulation similar to 
what has been shown for CD56bright NK cells, but are also capable of killing and producing 
cytokines after activating receptor stimulation as the rest of CD56dim NK cells, therefore rep-
resenting a unique subset of polyfunctional NK cells.  
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Figure 16: Analysis of cytotoxicity and cytokine production after activating receptor 
stimulation 
(A) Analysis of intracellular IFN-and TNF expression in CD56dim CD62L+ and CD62L- NK cells 
after stimulation with a combination of plate-bound mAb against NKp30, NKp46, NKG2D, 2B4 and 
CD2 or isotype control mAb; one representative experiment out of three is shown. (B) Analysis of 
cytotoxicity of CD56bright, CD56dim CD62L+ and CD62L- NK cells after K562 stimulation; mean ± SEM 
of nine independent experiments is shown. (C) Ex vivo expression of granzymeA (GRA), granzymeB 
(GRB) and perforin (Prf) (open histogram) and corresponding isotype control staining (gray-filled 
histogram) in CD56bright, CD56dim CD62L+ and CD56dim CD62L- NK cells; one representative donor 
out of three is shown. 
 
Since cytotoxic competence has been demonstrated to correlate with the presence of self-
MHC specific inhibitory receptors, it was investigated more in detail whether CD62L expres-
sion can influence NK cell competence within KIR3DL1+ cells (competent) or KIR- NKG2A- 
(hyporesponsive) cells in HLA-Bw4 donors. As previously shown (39, 40), expression of self-
MHC specific KIRs such as KIR3DL1 results in the most striking correlation with cytotoxic 
competence (Figure 17 A). However, expression of CD62L confers a slightly higher cytotoxic 
potential to both competent (KIR3DL1+) as well as hyporesponsive (KIR- NKG2A-) NK cells, 
which could result from recent in vivo activation of CD56dim CD62L+ NK cells by cytokines.  
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The degree of the effect associated with CD62L expression was comparable or even higher 
than the one associated with NKG2A (Figure 17 B). Interestingly, within hyporesponsive 
(KIR- NKG2A-) NK cells, those, which are potentially autoreactive, are almost exclusively 
included within the CD56dim CD62L+ subset (Figure 17 B). In the first two parts of this thesis 
it was shown that CD56dim KIR- (hyporesponsive) NK cells can up-regulate KIR after cyto-
kine stimulation (Figure 5) and that only those cells which de novo express self MHC specific 
KIR are licensed to kill (Figure 9). We therefore asked whether cytokine stimulation of 
CD56dim KIR- CD62L+ or KIR- CD62L- NK cells would result in comparable KIR de novo 
expression. As shown in Figure 17 C, KIR expression could be induced on both KIR- CD62L+ 
as well as KIR- CD62L- NK cells. However, a consistently higher proportion of KIR+ cells 
could be detected among CD56dim CD62L+ compared to CD62L- NK cells, suggesting that 
cells endowed with strong proliferative ability might have a higher chance to be licensed. 
 
 
Figure 17: Correlation of CD62L, KIR and NKG2A with cytotoxic competence 
(A) CD56dim NK cells derived from HLA-Bw4 donors were sorted for NKG2A- CD62L+ and NKG2A- 
CD62L- cells and stimulated for 6h with K562. CD107a expression was analysed within competent 
KIR3DL1+ 2D KIR- NKG2A- and hypo responsive KIR3DL1- 2D KIR- NKG2A- NK cell subsets after 
staining for KIR3DL1 (indicated as 3DL1) and 2D KIRs and gating on the indicated subsets: CD56dim 
CD62L+ cells are depicted in dark grey and CD62L- ones in light grey. Mean ± SEM of eight inde-
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pendent experiments is shown. * p<0.05; ** p<0.01; *** p< 0.0001 as calculated by Wilcoxon test, 
(B) CD56dim NK cells derived from HLA-Bw4 donors were sorted for CD62L and NKG2A expression 
and stimulated for 6h with K562. CD107a expression was analysed within 2D KIR- KIR3DL1+ or 2D 
KIR- KIR3DL1- cells. Mean values ± SEM of eight independent experiments are shown. * p<0.05; ** 
p<0.01; ns indicates p>0.05, as calculated by Wilcoxon test (C) Sorted CD56bright 2+3D KIR-, CD56dim 
2+3D KIR- CD62L+ or CD56dim 2+3D KIR- CD62L- NK cells were CFDA labelled, cultivated in the 
presence of IL-2 for 5 days and analysed for 2+3D KIR expression. Percentage of KIR induction is 
shown. One representative experiment out of three is depicted.  
 
4.3.6 CD56dim CD62L+ KIR- NK cells have intermediate telomere length between 
CD56bright and CD56dim CD62L- KIR+ NK cells
Since CD56dim CD62L+ NK cells have a more immature phenotype, i.e. being KIR- 
NKG2A+ CD27+ similar to CD56bright cells, and as they combine the ability to respond to cy-
tokines with the ability to respond to activating receptor stimulation, especially when self-
MHC specific KIR are coexpressed, CD56dim CD62L+ NK cells could represent an intermedi-
ate step of NK cell differentiation between CD56bright and CD56dim CD62L- cells. In order to 
test this hypothesis, telomere length in different NK cell subsets were measured. Comparative 
analysis of CD62L+ and CD62L- or of KIR+ and KIR- among CD56dim NK cells revealed no 
significant difference in telomere length (data not shown). However, telomere length analysis 
of cells, which have been sorted according to CD62L and KIR together, showed that CD56dim 
CD62L+ KIR- displayed intermediate telomere length between CD56bright and CD56dim 
CD62L- KIR+ NK cells (Figure 18 A). These data suggest that within the CD62L- subset, 
cells, which have acquired KIR expression, displayed the longest proliferative history and 
therefore differences in telomere length became detectable. Since loss of CD62L and acquisi-
tion of KIR expression appear to be uncoordinated events, and are probably induced by differ-
ent stimuli, CD62L+ KIR+ or CD62L- KIR- cells also exist but differences in their telomere 
length may not be substantial. It has been demonstrated that NK cells obtained from elderly 
people display increased frequencies of CD56dim cells and decreased frequencies of CD56bright 
cells (84), suggesting that terminally differentiated NK cells accumulate with ageing, similar 
to what has been shown for T cells (85). When we analysed the percentage of CD56bright, 
CD56dim CD62L+ and CD62L- NK cells in correlation to age, we found that frequencies of 
CD56bright as well as of CD56dim CD62L+ NK cells progressively decreased with ageing, while 
CD62L- cells increased (Figure 18 B).  
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Altogether these data suggest that CD56dim CD62L+ NK cells are enriched in cells display-
ing an intermediate step of maturation between CD56bright and CD56dim CD62L- NK cells. 
 
 
 
Figure 18: CD56dim CD62L+ NK cells have intermediate telomere length and decrease 
with ageing 
(A) Analysis of telomere length of CD56bright (black), CD56dim CD62L+ KIR- (dark grey) and CD56dim 
CD62L- KIR+ (light grey) NK cells, box plots with median and interquartile range of nine different 
donors are shown. * p<0.05; ** p<0.01 as calculated by paired students t test. (B) Analysis of percent-
age of CD56bright (r = -0.56, p= 0.003), CD56dim CD62L+ (r = -0.44, p=0.02, and CD56dim CD62L- (r = 
0.56, p=0.003) in correlation to age, Pearson correlation coefficient of 26 donors has been calculated. 
 
4.3.7 CD56dim CD62L+ NK cells have the potential to home to lymph nodes 
CD62L allows interaction with glycosylated L-selectin ligands on high endothelial venules 
and it is crucial for T cell and NK cell homing to lymph nodes (6, 86). However, it is unclear 
whether CD62L alone is sufficient to enter lymph nodes (87). CD56bright cells, which preferen-
tially reside in lymph nodes, express not only CD62L but also the chemokine receptor CCR7 
(8). Conversely, CD56dim NK cells are mostly CCR7- but express CXCR1, which enable them 
to migrate into inflamed tissues (8). In order to understand the migration potential of CD56dim 
CD62L+ cells, the expression of CCR7 and CXCR1 in NK cell subsets isolated ex vivo or after 
stimulation was reanalysed. CCR7 was indeed present not only on CD56bright but also on a 
small fraction of CD56dim cells. In line with CCR7 expression, few CXCR1- cells do also exist 
within CD56dim cells.  
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Interestingly, almost all CD56dim cells that were CCR7+ or CXCR1- were CD62L+ and a 
consistent proportion of them coexpressed CD27 (Figure 19 A). While CCR7 and CXCR1 
expression was mutually exclusive within CD56bright and CD56dim CD62L- cells, a minority of 
CD56dim CD62L+ cells coexpressed CXCR1 (Figure 19 A). Short IL-18 stimulation is able to 
induce CCR7 expression in CD56dim cells (59). When CD56dim CD62L+ and CD62L- cells 
were analysed for CCR7 expression after IL-18 stimulation, CCR7 was up-regulated by the 
majority of CD56dim CD62L+ cells (Figure 19 B) but only by a minor fraction of CD62L- 
ones. Altogether, these data suggest that CD56dim CD62L+ cells have the potential to home to 
lymph nodes similar to CD56bright cells. 
 
 
Figure 19: Analysis of chemokine receptor expression ex vivo and after stimulation of 
NK cell subsets 
(A) Ex vivo analysis of CCR7, CXCR1, CD62L and CD27 coexpression after gating on the indicated 
subsets; one representative donor out of three is shown. (B) Modulation of CCR7 expression after 
stimulation of sorted CD56bright, CD56dim CD62L+ and CD56dim CD62L- NK cells for 36 h in medium 
or in the presence of IL-18 
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5 Discussion
In the frame of this thesis, three central questions have been explored.  
First, the developmental relation between PB-CD56bright and CD56dim NK cells and potential 
sites of terminal NK cell maturation has been investigated. The data presented in the first part 
of this thesis provide new evidences strengthening the hypothesis that CD56bright may be pre-
cursors of CD56dim NK cells and that NK cell final maturation and acquisition of competence 
might occur in SLO during an inflammatory response. 
Second, it was analysed whether cytokines can induce expression of self specific inhibitory 
receptors and if so whether that would lead to education of hyporesponsive NK cells to be-
come competent and self tolerant. It could be demonstrated that cytokine induced expression 
of KIR leads to the generation of competent NK cells if the corresponding self-MHC mole-
cule is present in the donor.  
The aim of the third part of this thesis was to evaluate whether the expression of CD62L or 
other markers might be used to identify intermediate stages of NK cell maturation character-
ised by distinct functional properties and in line with that better define NK cell developmental 
history. It was shown that CD56dim CD62L+ cells represent an intermediate stage of NK cell 
maturation, which after restimulation can accomplish multiple functional tasks, and further 
develop into terminally differentiated effectors. This subset is unique in the way that it is re-
sponsive to cytokine stimulation as well as to activating receptor stimulation, abilities which 
are otherwise mutually exclusive in the rest of the NK cell population.  
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5.1 CD56bright NK cells display longer telomeres and acquire features of CD56dim
NK cells upon cytokine activation
 
Although the two main PB-human NK cell subsets, which are CD56bright and CD56dim NK 
cells, have been characterized regarding their functional properties, phenotype and tissue lo-
calisation, and despite progress in understanding NK cell specificity for target cells, less is 
known about stages of terminal NK cell maturation, expansion and site of differentiation, es-
pecially in the human system. In the first part of this thesis (chapter 3.1), the developmental 
relationship between CD56bright and CD56dim NK cells and the site of terminal human NK cell 
differentiation has been investigates more in detail. The data presented here show that after 
cytokine activation, in particular IL-2 and IL-15, CD56bright NK cells could acquire the signa-
ture of CD56dim NK cells, i.e. KIR+ CD16+ IL7R- c-kit- CXCR3- CCR7-, CD62L-, while 
CD56dim CD16+ KIR+ NK cells maintain their features of terminally differentiated cells. 
Within the molecules induced in CD56bright NK cells, KIRs are of great interest. In contrast to 
CD16 expression, which has been shown to be differentially modulated depending on the 
stimuli (Figure 4) or the experimental model used (58, 59), KIR expression remains stable as 
shown in NK cell clones under varying cell culture conditions and activation stimuli (88, 89). 
Clonal patterns of KIR expression are mainly epigenetically regulated and maintained through 
DNA methylation (88, 89). In line with that, so far KIR expression was induced in vitro only 
using methyltransferase inhibitors. However, as demonstrated in the present study, both 
CD56bright KIR- and CD56dim KIR- NK cells could express KIR on a subset of cells after cyto-
kine stimulation. This result is in fact in contrast to a previous publication where it was 
claimed that no KIR or CD16 up-regulation was occurring on CD56bright NK cells after IL-2 
stimulation (9). One possible explanation for this discrepancy might rely on the different ex-
perimental conditions (e.g. IL-2 concentration).  
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The evidence that KIR are molecules inducible on NK cells raises interest about the 
mechanisms by which this process can occur, since this understanding might help to clarify 
the mechanisms underlying NK cell tolerance to self. For long time it was claimed that each 
NK cell expresses at least one inhibitory receptor specific for self-MHC class I thereby ensur-
ing tolerance towards self. However, recent studies have changed the view on how NK cell 
self-tolerance is achieved, showing that NK cells, which do not express inhibitory receptors 
recognizing self-MHC, do exist. Nonetheless, only NK cells expressing self-MHC specific 
inhibitory receptors are competent, while those lacking such receptors display an anergic phe-
notype (37-39, 41, 42). In this context, the finding that KIR can be induced by cytokines is of 
great interest because it suggests that NK cell self-tolerance might be a dynamic process 
probably related to cell differentiation: Cytokines produced during an inflammatory response 
by DC or T cells could induce NK cell differentiation and thereby generation of new compe-
tent NK cells. Along this line, it has been shown that also Ly49 molecules, the corresponding 
receptors in mice, can be modulated on NK cells after cytokine stimulation, suggesting a simi-
lar scenario in mice (90).  
As shown in Figure 5, KIR+ NK cells showed lower ability to proliferate in response to cy-
tokines compared not only to CD56bright but also to CD56dim KIR-. This surprising finding was 
not due to a mAb staining artefact (e.g. inhibition of proliferation via triggering of inhibitory 
receptors by anti-KIR mAb) since staining or not total CD56dim NK cells (mixture of KIR+ 
and KIR- NK cells) with anti-KIR mAb combination used for the sorting procedure did not 
influence at all NK cell proliferation (data not shown). One possible explanation of the lower 
CD56dim KIR+ NK cell proliferation might be due to KIR binding in cis or in trans to surface 
MHC class I molecules expressed on NK cells, which could result in inhibition of prolifera-
tion after stimulation, as it has been shown for cis-binding of Ly49 in mice (91). Nonetheless, 
since, also in this case, staining of KIR with mAb should influence KIR ability to bind MHC 
class I molecules and resulting in less inhibition, this is rather unlikely. Given all these obser-
vations, the hypothesis can be favoured that CD56bright and CD56dim NK cells do not belong to 
two distinct subsets, but rather that CD56bright represent an earlier stage of NK cell develop-
ment and that KIR acquisition correlates with a terminal step of NK cell maturation, as it has 
been already speculated both for NK cells and CD8+ KIR+ T cells (92, 93).  
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As shown already for T cells, terminal differentiation towards an effector cell type goes 
along with the loss of proliferative capacity. Next, modulation of cytokine receptors, such as 
the stem cell factor receptor CD117 (c-kit) and CD127 (IL7R), that have been shown to be 
present not only on CD56bright but already on NK cell immature precursors in humans and in 
mice (55, 94) has been investigated. It could be shown that these receptors were also down 
regulated on CD56bright NK cells during cytokine-induced proliferation. The progressive loss 
of these receptors is also very suggestive of a differentiation process from an early to a more 
advanced stage at which NK cells do not require stem cell factor or IL-7 signalling any longer. 
Accordingly, mouse Maclow NK cells displaying an immature phenotype tend to express c-kit, 
which is then absent in mature Machi NK cells (94). CD56bright NK cells express lymph node 
homing receptors such as CD62L, CXCR3 and CCR7 and represent the majority of NK cells 
found in SLO. Down-regulation of these SLO homing molecules on CD56bright NK cells upon 
cytokine stimulation, as shown in Figure 3, is consistent with the hypothesis that these NK 
cells would leave SLO after their activation. In vitro differentiation of CD56bright NK cells 
towards a phenotype akin of CD56dim NK cells was often accompanied by extensive NK cell 
proliferation induced by cytokine stimulation. Thus, if CD56bright NK cells represented an ear-
lier developmental step of NK cell differentiation, they should have undergone a lower num-
ber of proliferative events in vivo. To test this hypothesis, telomere length of CD56bright, 
CD56dim an LN-NK cells in comparison to naive and memory T cells were evaluated, since in 
most normal somatic cells telomere length inversely correlates with proliferative history. 
CD56bright NK cells displayed longer telomeres than CD56dim NK cells, and telomere-
shortening in CD56dim compared to CD56bright was similar to the one observed in memory T 
cells compared to naive T cells. In this regard, CD56bright exhibit the same characteristics as 
naïve T cells, i.e. longer telomeres compared to memory T cells, in according to previous re-
ports (72). Although not providing the definitive proof that CD56bright are the precursors of 
CD56dim NK cells, these results definitely rule out the possibility that CD56bright are derived 
from CD56dim ones. Very recently, other studies have provided further evidences that 
CD56bright are the precursors of CD56dim NK cells. Indeed, it was shown that CD56bright NK 
cells acquire the phenotype of CD56dim cells after in vitro culture with IL-15 and murine stro-
mal cells (78) or with human fibroblasts and that CD56bright NK cells have longer telomeres 
than CD56dim ones (95). Furthermore, a study in humanized Rag2-/-c -/- reconstituted with 
human HPC supports an IL-15 dependent linear differentiation from immature CD56bright 
CD16- KIR- over CD56dimCD16+ KIR- to CD56dim CD16+ KIR+ NK cells (96). Altogether, the 
results obtained in this thesis together with other published data strongly support the concept, 
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that CD56bright NK cells are more immature and can give rise to CD56dim NK cells under the 
influence of cytokines. 
To get an idea what could be actually the site of terminally differentiation of CD56bright into 
CD56dim NK cells, ex vivo analysis of human NK cells from different compartments were per-
formed. This analysis revealed that non-reactive LNs contain almost exclusively CD56bright 
KIR- CD16- NK cells while a significant expression of KIR and CD16 on NK cells was pre-
sent in highly inflamed LN and in the efferent lymph. These data suggest that CD56bright KIR- 
CD16- NK cells can acquire KIR and CD16 in inflamed LN and then circulate as KIR+ CD16+ 
NK cells via the efferent lymph in PB. The assumption that cytokines released during inflam-
mation can mobilize NK cells from SLO to PB is also supported by previous studies reporting 
that recombinant IL-2 therapy for human cancer results in a striking increase of CD56bright 
CD16+ NK cells in PB (24). CD56bright KIR- NK cells may re-circulate through SLO or reside 
there where they become activated by cytokines inducing proliferation and maturation into 
KIR+ CD16+ cytotoxic NK cells, and later leave LN in order to reach inflamed tissues. Al-
though this hypothesis is very challenging, it cannot be excluded that the presence of KIR+ 
CD16+ NK cells in inflamed LN and in the efferent lymph might be due to selective migration 
of this subset into LN and not to CD56bright differentiation into CD56dim NK cells. Nonethe-
less, since it has been shown that NK cell recruitment into inflamed LN occurs via CD62L 
and CXCR3 (6), KIR+ CD16+ NK cells, which are preferentially CD62L- and CXCR3-, should 
be less prone to migrate to this site.  
There are other studies suggesting that LN may represent a key site for NK cell develop-
ment (52, 55). In fact, it has been recently shown that four different developmental stages of 
human NK cell precursors are present in LN and that differentiation from these precursors to 
mature CD56bright NK cells can be mediated by cytokines and are supported by stromal cells 
(52, 55). However, from these previous observations it is not yet clear to what extent NK cell 
differentiation in SLO might account for the total mature NK cell compartment in the body, as 
most NK cells in human PB are CD56dim. The data presented in this thesis suggest that also 
final maturation of CD56bright into CD56dim might occur in SLO, further supporting the hy-
pothesis that CD56dim NK cells might correspond to the terminally differentiated stage of hu-
man NK cell development. Although reactive SLO might represent an important site of NK 
cell differentiation and maturation, such differentiation processes could also take place in 
other inflamed tissues, where both CD56bright and CD56dim NK cells can be found (97).  
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Whatever the case, it would be very interesting to investigate which cell type resident in 
the LN is crucial to induce NK cell proliferation and maturation. One interesting candidate is 
the dendritic cell (DC) since NK cells and DCs are colocalized in LN paracortex and medulla, 
and have been shown to interact with each other over extended times (98, 99). Since it was 
previously shown that both myeloid and plasmacytoid DCs can induce selective expansion of 
CD56bright NK cells (70, 99, 100), it would be important to determine whether DCs can induce 
not only CD56bright proliferation but also differentiation into CD56dim NK cells. To this aim, 
whether DCs can induce KIR and CD16 expression on proliferating CD56bright NK cells 
should be analysed. It is also not clear at which phase of an immune response NK cell final 
maturation may happen. Both DC- (IL-15 and to some extent IL-12) and T cell- (IL-2) derived 
cytokines can induce this differentiation step in vitro. If DC-derived cytokines were primarily 
involved in NK cell maturation in vivo, this process could take place in the very early phase of 
an innate immune response before T cell clonal expansion. However, considering the effect of
IL-2 in vitro and the significant in vivo association between KIR/CD16 expression and para-
cortical/follicular hyperplasia where extensive lymphocyte proliferation occurs, it is conceiv-
able that NK cell terminal differentiation could take place later on during an immune re-
sponse, when proliferating naïve T cells start to produce high amounts of IL-2. 
In conclusion, the data presented in the first part of this thesis provide new evidences sup-
porting the hypothesis that CD56bright may give raise to CD56dim NK cells and a scenario in 
which NK cell final maturation and acquisition of competence might occur in SLO during an 
inflammatory response can be hypothesized. 
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5.2 Cytokines induce stable expression of inhibitory receptors on hyporespon-
sive CD56dim KIR- NKG2A- NK cells
 
In the first part of this thesis it could be demonstrated that cytokines such as IL-2, IL-15 and 
to a lower extend IL-12 can induce de novo expression of KIR in PB- or LN-derived 
CD56bright KIR- or CD56dim KIR- NK cells. Additionally, it was shown that KIR+ NK cells are 
detectable only in highly reactive lymph node, characterized by lymphocyte expansion and 
cytokine production. Since expression of self-MHC class I specific inhibitory receptors such 
as KIR and NKG2A is essential to ensure self-tolerance and to render a NK cell functional 
competent, it was investigated whether cytokine induced expression of self-specific inhibitory 
receptors would be enough to educate KIR- NKG2A- hyporesponsive NK cell. The data pre-
sented in the second part of this thesis (chapter 3.2) provide the first evidence that acquisition 
of KIR expression after cytokine stimulation leads to education of hyporesponsive NK cells. 
In fact, it was clearly demonstrated that cytokines are able to induce stable KIR expression on 
a subset of hyporesponsive KIR- NKG2A- NK cells. Since KIR+ cells have a much lower pro-
liferative capacity as compared to KIR- ones (Figure 5) (78), NK cells which acquired KIR 
expression were more or less lost after four weeks of culture. That could be the reason why 
KIR induction by cytokines has been underestimated in previous studies (78, 95). Nonethe-
less, when KIR3DL1+ NK cells were re-sorted after 12 days of culture in order to minimize 
the bias of KIR- cell overgrowth, most NK cells maintained KIR expression, similar to ex vivo 
KIR3DL1+ ones. Several groups have used murine stromal cells (78) or human fibroblasts 
(95) in addition to cytokines in order to achieve KIR induction in NK cells. However, as 
shown in Figure 5, 7 and 8, cytokines alone in the absence of any accessory cells were able to 
induce KIR expression, but that was restricted to a small subset of NK cells. Interestingly, 
cells that failed to acquire KIR in a first round of cytokine stimulation were also not able in a 
second round. Therefore, one could hypothesize that some NK cells already received in vivo a 
signal leading to the initiation of KIR expression and that cytokines would only promote the 
preferential expansion of this committed subset in vitro. However, a recent report from 
Cichocki et al demonstrated that IL-15 or IL-2 induce c-Myc binding to an upstream distal 
KIR promoter element which promotes KIR transcription (101), supporting the idea that cyto-
kines are directly required for induction of KIR expression and do not only allow the prolif-
eration or differentiation of a subset of committed NK cells.  
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Even if it cannot be ruled out that further unknown signals might be required, the results pre-
sented in this thesis clearly show that cytokines are essential to induce stable KIR de novo 
expression in a subset of hyporesponsive NK cells.  
Next, it was investigated whether cytokine induced KIR acquisition was associated with edu-
cation of former hyporesponsive NK cells. It could be demonstrated that hyporesponsive NK 
cells which acquired KIR after cytokine stimulation became cytotoxic competent, suggesting 
that hyporesponsiveness is not a permanent feature but can be modulated under certain cir-
cumstances. Several in vivo data provided a hint that hyporesponsive NK cells which do not 
express inhibitory receptors can still function during infectious diseases (37, 43). Besides, it 
has been controversially discussed whether IL-2 stimulation could reverse NK cell hypore-
sponsiveness (39, 78). In the system used in the study presented here, only acquisition of self-
MHC specific KIR (i.e. KIR3DL1 in HLA-Bw4 individuals) correlates with induction of cy-
totoxic competence, while acquisition of non self specific KIR (i.e. KIR3DL1 in HLA-Bw6 
individuals) does not. These data show that although KIR de novo expression can occur also 
in the absence of the cognate MHC molecule, in agreement with the stochastic nature of the 
KIR repertoire (36), acquisition of cytotoxic competence requires the presence of self-MHC. 
Since cytokine stimulation can confer competence in the absence of any accessory cells, KIR 
could engage the cognate MHC molecule expressed on the same NK cell (cis interaction) or 
on neighbouring NK cells (trans interaction). In mice, it has been recently shown that cis in-
teraction between inhibitory Ly49A receptor and MHC class I molecules plays a role for edu-
cation of NK cells (102). Even if the hypothesis that human NK cell education as well is me-
diated via cis interaction would be very intriguing, there is currently no evidence that the 
function of KIR is influenced by HLA expression in cis (103). The observation that self-MHC 
molecules expressed on the surface of NK cells can be sufficient to induce NK cell education 
has important implications in HLA-mismatched hematopoietic stem cell transplantation, 
where alloreactive NK cells have been shown to be beneficial especially for the treatment of 
acute myeloid leukemia (104). Since these NK cells would develop and therefore be educated 
in an KIR-MHC class I mismatched environment it would be of interest, which cells are in
vivo responsible for educating NK cells. Finally, it was shown that cytokine induced KIR are 
actually functional, since they are able to inhibit NK cell killing of target cells expressing the 
cognate MHC ligand, thus suggesting that cytokine induced education should not lead to 
autoreactivity.  
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Altogether, the results show that competent NK cells can be generated after cytokine stimula-
tion, thus indicating that hyporesponsiveness does not represent an irreversible state. On the 
contrary, at least a subset of hyporesponsive NK cells can still be educated to become compe-
tent and self tolerant during an immune response. As it was previously shown that KIR acqui-
sition can occur in highly reactive LN (Figure 6), inflamed secondary lymphoid organs might 
represent one possible peripheral site of NK cell education in vivo. This process requires the 
expression of the cognate MHC ligand and can occur in the absence of any accessory cells.  
These results help to clarify the means by which NK cell education is achieved, and might 
have important implications especially in haploidentical transplantation, where competence of 
donor alloreactive NK cells reconstituted in MHC mismatched recipients has not been ad-
dressed yet. 

5.3 CD62L expression identifies a subset of polyfunctional CD56dim NK cells 
 
To dissect further the heterogeneity of CD56dim cells, in the third part of this study (chapter 
3.3) an extensive ex vivo analysis of human NK cells has been performed according to the 
expression of markers related to differentiation, migration or competence. In particular, 
CD56dim cells have been further dissected according to the expression of the lymph node hom-
ing marker CD62L. Thus, a new subset of polyfunctional NK cells could be identified since it 
was shown that CD56dim CD62L+ NK cells represent the only human NK cell subset endowed 
with full effector functions after stimulation with cytokines and via activating receptors as 
well as with high self renewable ability.  
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It could be demonstrated that both CD56bright and CD56dim CD62L+ cells are actively pro-
liferating in vivo under steady state conditions as well as in the course of an acute viral infec-
tion such as yellow fever infection. In vivo proliferation of NK cells under steady state condi-
tions and in the early phase of a viral infection, is largely non-specific and most probably 
cytokine driven (105, 106). Thus, IL-15 has been shown to be the limiting factor for homeo-
static expansion of NK cells (107, 108) and there are evidences that IFN-	 induced IL-15 is 
also involved in virus-induced NK cell proliferation (109, 110). Considering the high respon-
siveness of CD56bright and CD56dim CD62L+ NK cells to cytokines, it is likely that Ki67+ cells 
within these NK cell subsets might have been activated in vivo by cytokines. The high ability 
of CD56dim CD62L+ cells to respond to -chain cytokines was associated to elevated levels of 
STAT5 phosphorylation. Efficiency of STAT or ERK activation after cytokine stimulation has 
been correlated to the amounts of SET, a potent inhibitor of protein phosphatase 2A (PP2A) 
activity (81). Trotta et al. have indeed shown that SET expression is higher in CD56bright than 
in CD56dim cells and knocking down of SET resulted in decreased STAT5, STAT4 and ERK 
phosphorylation after cytokine stimulation (81).  
Cytokine and DC stimulation resulted also in massive IFN- production by CD56bright and 
CD56dim CD62L+ cells while CD62L- cells were very inefficient. CD56dim NK cell ability to 
proliferate and to produce IFN- after DC or cytokine stimulation stringently correlated with 
CD62L and not with KIR or NKG2A expression. Therefore, the higher proliferative compe-
tence of KIR- or NKG2A+ cells observed in previous reports (Figure 5) (78), might rather be a 
consequence of enrichment of CD62L+ NK cells in these populations, and not of a direct cor-
relation to one of these markers. Interestingly, among CD56dim CD62L+ and CD62L- NK 
cells, CD27 expression identified NK cells with a higher capacity to produce IFN-, showing 
that the combination of CD62L and CD27 (but not CD27 alone) identifies the most potent 
IFN- producers among CD56dim NK cells. Although CD56bright have been long considered as 
the cytokine producers, these cells were almost unable to express IFN- and TNF after activat-
ing receptor stimulation, while CD56dim CD62L+ as well as CD62L- cells were conversely 
very efficient. In line with IFN- and TNF expression after activating receptor stimulation, 
cytotoxicity against MHC class I negative target cells was very poor in CD56bright but compa-
rable in both CD56dim CD62L+ and CD62L- cells.  
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While expression of self-MHC-specific KIR or NKG2A seemed to have no influence on 
the capacity to proliferate and to produce IFN-, NK cells bearing a self-MHC class I specific 
KIR were more cytotoxic than KIR- cells with just minor enhancing impact of CD62L or 
NKG2A, probably reflecting a recent in vivo activation by cytokines. Acquisition of KIR 
clearly represents a crucial step during NK cell differentiation, since cytotoxic cells were 
mostly included within NK cells expressing self- MHC specific KIR, in line with previous 
results (39, 40). Concerning NKG2A, it was already reported that its influence on NK cell 
competence is rather low compared to self-MHC-specific KIR (40). When analysing the im-
pact of NKG2A versus KIR or CD62L expression on cytotoxic competence, it was shown that 
NKG2A expression per se is almost irrelevant. The reported influence of CD27 expression on 
cytotoxic capacity of NK cells is difficult to interpret. In mice, it has been shown that CD27+ 
cells are more cytotoxic whereas in humans CD56dim CD27+ cells were less cytotoxic (66, 
111) then CD27- ones. Both studies did not take into account the influence of self-MHC-
specific inhibitory receptors. Since CD27 expression negatively correlates with KIR or Ly49 
receptor expression in total NK cells (65, 66, 111), as well as within the CD56dim subset (p = 
0.002, data not shown), definite conclusions cannot be driven from published results. In order 
to assess this issue, analysis of cytotoxicity should be performed on CD27+ and CD27- cells 
expressing or not self-MHC specific KIR. However, due to the extremely low number of 
CD27+ KIR+ cells, this experiment is rather challenging. Based on the results obtained in this 
study, it seems that the ability to proliferate and to produce IFN- in response to cytokines is 
clearly dissociated from the ability to kill and to produce IFN- after activating receptor 
stimulation in most NK cells with the exception of CD56dim CD62L+ cells, which therefore 
represent a unique polyfunctional subset. CD56dim CD62L+ NK cells are special not only in 
relation to their functions but also to their homing potential. Indeed, the data presented here 
suggest that a fraction of CD56dim CD62L+ NK cells would has the potential to migrate 
through high endothelial venules and to patrol secondary lymphoid tissues, similar to what has 
been shown for central memory T cells (112). Due to their homing potential as well as func-
tional properties, CD56dim CD62L+ cells indeed resemble central memory T cells. Recent 
studies suggested that NK cells primed during viral infections or by cytokines may exhibit 
memory-like properties during a recall viral response or ex vivo restimulation (63, 64). It is 
exciting to speculate that the CD56dim CD62L+ subset might be enriched in cells that received 
priming in vivo. Hence, these cells might be able to respond rapidly after restimulation in a 
memory like fashion and further develop into terminally differentiated effectors. Although no 
data could be provided sustaining this hypothesis, the analysis of telomere length at least sup-
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ports the idea that CD56dim CD62L+ KIR- NK cells may represent an intermediate step of 
maturation between CD56bright and CD56dim CD62L- KIR+ ones, as also suggested by their 
phenotype and functions. The finding that differences in telomere length within CD56dim sub-
sets became detectable only when comparing CD56dim CD62L- KIR+ with CD62L+ KIR- cells, 
give rise to different interpretations. The favoured explanation is that, among the CD62L- sub-
set, cells that acquired KIR expression displayed the longest proliferative history, and thus 
differences in telomere length became detectable. Since loss of CD62L and acquisition of KIR 
expression appear to be independent events, CD56dim CD62L+ KIR+ or CD62L- KIR- cells 
also exist, but differences in their telomere length may not be substantial. However, since un-
der selected stimuli CD62L can be up regulated (Figure 3), CD62L+ KIR+ cells may also in-
clude a contamination of “revertants”, which have reacquired CD62L expression. The idea 
that CD56dim CD62L- cells may be enriched in terminally differentiated cells fits also to the 
observation that those cells accumulate with age, while frequencies of CD56bright and CD56dim 
CD62L+ cells decrease. Absolute NK cell numbers tend to be maintained or to increase with 
age (113, 114), and the accumulation of NK cells seems to be a consequence of an increase in 
the mature CD56dim subset rather than in the less mature CD56bright one (84). The longer infec-
tious history of aged people could result in repeatedly stimulation and expansion of CD56dim 
CD62L+ NK cells accompanied by a progressive differentiation towards CD56dim CD62L- 
CD27- KIR+ NK cells going over several intermediate stages detectable in the peripheral NK 
cell pool. The concept is also in line with results obtained in a recent study describing NK cell 
reconstitution in patients undergoing hematopoietic stem cell transplantation (HSCT) (115). 
Indeed, most of the NK cells derived from PB of patients at day 30 after HSCT were 
CD56bright as previously shown (56), and almost all CD56dim NK cells expressed CD62L. Per-
centages of CD56dim CD62L+ NK cells progressively decreased with time and became compa-
rable to those of healthy blood donors only around 100 days after HSCT (115). 
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Based on all these results as well as on many previous observations (53), it can be pre-
sumed that early CD56bright NK cells display high ability to respond to DC derived cytokines, 
which represent the main activating signal in secondary lymphoid organs where CD56bright NK 
cells reside, but exhibit poor effector functions after activating receptor stimulation. Cytokines 
provided by DC such as IL-15 (62), IL-18 (60) or IL-12 (61) could be at least one important 
factor responsible for NK cell priming and NK cell differentiation into CD56dim. After res-
timulation, NK cells would progressively lose their ability to respond to cytokines but would 
acquire the capacity to display effector functions upon activating receptor stimulation. This 
property is indeed crucial for a prompt response against infected cells in inflamed tissues. 
These events would be accompanied by progressive loss of CD62L, CCR7 and CD27 and 
acquisition of KIR and CXCR1, as also supported by several other studies (57, 66, 77, 78, 96, 
116). In this scenario, CD56dim CD62L- KIR+ (CD27-) cells might correspond to terminally 
differentiated effector NK cells, while CD56dim CD62L+ NK cells may represent cells that 
patrol secondary lymphoid organs and, when restimulated, display direct effector functions 
and give rise to terminally differentiated effectors.  
The results presented in the third part of this thesis provide further insights into differentia-
tion history of human NK cells and identifies a unique subset of polyfunctional NK cells. Due 
to their versatility, CD56dim CD62L+ NK cells might be important in the defence against 
pathogens or as immune correlates of protection in vaccination, as it has been shown for poly-
functional T cells (117-119). Moreover, this subset could be an optimal candidate for adoptive 
NK cell therapy that has been shown to be a feasible strategy to improve cancer therapy in 
combination or not with HSCT (104, 120).  
Overall, this thesis provides new insights into terminal human NK cell differentiation that 
goes via several intermediate stages which are characterized by distinct functional properties. 
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Human NK cells comprise two main subsets, CD56br and CD56dim cells. In this study, an 
extensive analysis of human NK cell phenotype and functional characteristics has been per-
formed in order to investigate the developmental relation between NK cell subsets, to eluci-
date how NK cell competence is acquired and to further dissect the heterogeneity of the 
CD56dim subset with regard to functions and differentiation history of human NK cells.  
It could be shown that upon cytokine activation, CD56br differentiate into CD56dim NK 
cells and that this process might take place in inflamed secondary lymphoid organs (SLO). 
One of the crucial markers acquired during this process is KIR, the main MHC-specific in-
hibitory receptors responsible for self versus non self recognition. Previously, it has been 
shown that only cells expressing self-MHC specific KIRs are responsive to activating stimuli. 
In this study, it was demonstrated that induction of self-MHC specific KIR by cytokines leads 
to acquisition of functional competence. Ex vivo analysis of human tissues suggests that ac-
quisition of KIR and consequently of cytotoxic competence may occur in inflamed SLO. Fi-
nally, it was demonstrated that CD56dim NK cells do not represent a homogenous population. 
When dissected for CD62L and KIR expression, a new subset of NK cells could be identified, 
namely CD56dimCD62L+, which uniquely combines properties of CD56br NK cells, particu-
larly high IFN- production upon cytokine stimulation, proliferation and potential to migrate 
into SLO, with the capacity of CD56dim to kill, produce cytokines upon activating receptor 
stimulation and to migrate into inflamed tissues. Ex vivo analysis of the function, phenotype, 
telomere length and frequencies during ageing of CD56br, CD56dimCD62L+ and 
CD56dimCD62L- NK cells suggest that CD56dimCD62L+ cells represent an intermediate stage 
of NK cell maturation between the more immature CD56br and the terminally differentiated 
CD56dim CD62L- NK cells.  
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7 Zusammenfassung
 
Humane NK Zellen können in CD56br und CD56dim NK Zellen unterteilt werden. In dieser 
Arbeit wurde untersucht, in welchem Zusammenhang die verschiedenen NK Zell Populatio-
nen stehen und wie funktional kompetente NK Zellen generiert werden. Des Weiteren wurde 
die Heterogenität der CD56dim NK Zell Population in Bezug auf Funktionalität und Differen-
zierungsstadien analysiert. 
Es konnte gezeigt werden, dass CD56br NK Zellen in CD56dim NK Zellen differenzieren. 
Währenddessen werden u.a. MHC-I spezifische inhibierende Rezeptoren (KIR) erworben. 
Diese sind essentiell für die Unterscheidung zwischen “Selbst” und “Nicht-Selbst”, wobei nur 
NK Zellen, die Selbst-MHC-spezifische KIRs tragen, funktional kompetent sind. In der vor-
liegenden Arbeit konnte darüber hinaus gezeigt werden, dass zuvor anerge NK Zellen nach 
Zytokin-induzierter Expression eines Selbst-MHC-spezifischen KIRs kompetent werden. Ex 
vivo Analysen humaner Gewebe lassen vermuten, dass diese Prozesse während einer Entzün-
dung in sekundären lymphatischen Organen (SLO) stattfinden könnten.  
Auch CD56dim NK Zellen selbst sind nicht homogen, hingegen können anhand der Expres-
sion von KIRs oder CD62L, welches für die Migration in SLO wichtig ist, weitere Subpopula-
tionen unterschieden werden. Eine umfassende Analyse bezüglich KIR und CD62L Expressi-
on führte zur Identifizierung einer zuvor nicht charakterisierten CD56dimCD62L+ NK Zell 
Population, welche die Fähigkeiten von CD56br, Zytokine zu produzieren und zu proliferieren, 
mit einem hohen zytotoxischen Potenzial, vereinigt.  
Weitere ex vivo Untersuchungen des Phänotyps, der Telomerlängen und der Verteilung in 
Relation zum Alter lassen vermuten, dass die Differenzierung humaner NK Zellen von CD56br 
über CD56dimCD62L+ zu CD56dimCD62L- verläuft, wobei die Zellen mit fortschreitender Dif-
ferenzierung ihre Fähigkeit auf Zytokine zu antworten verlieren und dafür die Fähigkeit er-
langen, über aktivierende Rezeptoren stimuliert zu werden. 
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9 Appendix
Appendix                                                                        I 
 
I Abbreviations 
 
    anti 
ADCC   antibody dependent cellular cytotoxicity 
APC   antigen presenting cell 
BCR   B cell receptor 
BSA   bovine serum albumin 
BM   bone marrow 
BrefA   Brefeldin A 
CD   cluster of differentiation 
CFDA    Carboxyfluoresceindiacetat 
CFSE   Carboxzfluoresceinsuccimidylester 
CTL   cytotoxic T lymphocyte 
DC   dendritic cell 
EDTA   ethylene diaminetetraacetic acid 
ERK   extracellular signal-regulated kinase 
FACS   fluorescence activated cell sorting 
FcRIII   constant fraction  receptor III 
FCS   forward scattered light 
g    Relative centrifuge force (g = 9.81 m/s2) 
GM-CSF  granulocyte-macrophage colony-stimulating factor 
HLA   human leukocyte antigen 
HPC   hematopoietic progenitor cell 
IFN-   interferon  
IL    interleukin 
ITIM   immunoreceptor tyrosine-based inhibitory motif 
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KIR   killer immunoglobuline-like receptor 
LN   lymph node 
LPS   lipopolysaccharide 
mAb   monoclonal antibody 
MACS   magnetic activated cell separation 
MHC   major histocompatibility complex 
MFI   mean fluorescence intensity 
Monokine  monocyte-derived cytokine  
mDC   myeloid DC 
NCR   natural cytotoxicity receptors 
NK    natural killer 
NKR   NK receptor 
PAMP   pathogen associated molecular pattern 
PB   peripheral blood 
PBMC   peripheral blood mononuclear cells 
PBS   phosphate buffered saline 
PI    propidium iodide 
RPMI   Roswell Park Memorial Institute 
RTL   relative telomere length 
ORF   open reading frame 
SA   Streptavidine 
SLO   secondary lymphoid organs 
SSC   side scatter 
STAT   Signal Transducers and Activator of Transcription 
TCR   T cell receptor 
TH    T helper  
TLR   Toll-like receptor 
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TNF   tumour necrosis factor  
YFV   yellow fever virus 
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